WO2006038738A1 - 受容体機能調節剤 - Google Patents
受容体機能調節剤 Download PDFInfo
- Publication number
- WO2006038738A1 WO2006038738A1 PCT/JP2005/018908 JP2005018908W WO2006038738A1 WO 2006038738 A1 WO2006038738 A1 WO 2006038738A1 JP 2005018908 W JP2005018908 W JP 2005018908W WO 2006038738 A1 WO2006038738 A1 WO 2006038738A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- reference example
- optionally substituted
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Definitions
- the present invention relates to a GPR4 O: body function regulator useful as an agent for preventing / treating obesity, hyperinsulinemia, type 2 diabetes and the like.
- GPR40 is one of the G protein-coupled receptors (GPCRs). GPR40 antagonists and antagonists are type 2 diabetes, obesity, impaired glucose tolerance, insulin resistance, nerve It has been reported to be useful as a therapeutic drug for degenerative diseases (eg, Alzheimer's disease) (see International Publication No. 02 No. 05 7 783 pamphlet).
- GPCRs G protein-coupled receptors
- GPR40 receptor function regulators GPR40 agonist is diabetic, impaired glucose tolerance, ketosis, acidosis, diabetic
- GPR40 antagonist is useful as a preventive and therapeutic agent, obesity, hyperlipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, edema, Prevention against diseases such as insulin resistance syndrome, unstable diabetes, fat atrophy, insulin allergy, insulinoma, arteriosclerosis, thrombotic disease, lipotoxicity, hyperinsulinemia, cancer ⁇ It has been reported to be useful as a therapeutic agent (see WO 04 0 41 266 pamphlet
- R 1 and R 2 are independently, R 3; R 8; NHR 3; NHR 5; NHR 6; NR 5 R 5; NR 5 R 6; SR 5; SR 6; SR 3; OR 5 ; oR 6; oR 3; C (O) R 3; optionally substituted with or 1-4 independent R 4; Teroshiku Lil also to be substituted with 1-4 independent R 4 Good Ci one! .
- R 3 is independently aryl; phenyl optionally substituted with 1 to 5 independent R 4 ; or heteroalkyl optionally substituted with 1 to 4 independent R 4
- R 1 and R 2 are independently hydrogen atom, halo, hydroxy, - 4 ⁇ alkyl, Nono b - 4 alkyl such as; R 3 and R 4 are independently hydrogen atom, halo C. Alkyl, or an optionally substituted _ 6 alkyl, and the like; or R 3 and R 4, together with the nitrogen atom to which they are attached may be substituted, fully saturated, heterocyclic partially saturated or fully unsaturated A ring; R 5 is C 4 _ alkyl, etc.) has been reported to have OR L-1 receptor agonist activity and to be useful as an analgesic. (See EP 1 06 9 1 24).
- R 1 is a hydrogen atom, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyan, isocyano or azide
- R 2 is a hydrogen atom, hydroxy, alkoxy, chlorine, bromine or iodine
- X is 0, S or CH 2
- a, b, c and d are 4 An asymmetric carbon atom substituted with a different substituent
- B is a purine base, an oxidized purine base, or a pyrimidine base). It has been reported (see WO 02/18404 pamphlet).
- X is N or CH; Y is 0, S, SO, S0 2 or NH; k is 0 or 1; m is 0, 1 or 2; R 1 is phenyl, pyridyl, dihydropyridyl — It is reported that the compound represented by (4) one-on group; R 2 represents a phenyl group, a pyridyl group, a substituted phenyl group, etc.) is useful as a therapeutic agent for liver disease (International Publication No. 99). / See the 57103 pamphlet).
- ring A represents a pyridyl group or substituted pyridyl group
- ring B represents a phenyl group; Or a substituted phenyl group
- R 1 and R 2 represent a hydrogen atom, or together form one (CH 2 ) q—; m is 1 or 2; n is 0, 1 or 2; q represents 3 or 4] is reported to be useful as an anti-ulcer agent (see US Pat. No. 4,996,217).
- Q represents a carbonyl group or one CH (A r) group;
- a r represents a phenyl group or a halophenyl group;
- R represents a linear or branched lower alkyl group, an aralkyl group, It is reported that the compound represented by the formula (showing a benzoyl lower alkyl group etc.) is useful as a psychotropic drug (see JP-A-51-70766).
- R 1 represents a hydrogen atom, - 8 alkyl, heteroaryl d _ 8 alkyl, Furuo port - 4 alkyl, cycloalkyl C - 8 alkyl, heterocyclo - 8 alkyl, Ariru, Ariru one s alkyl, cyclo C 3 - 8 Alkyl I C
- R 2 is C - 8 alkyl, terrorist to C - 8 alkyl, Pafuruoro C i one 4 alkyl, Ariru or heteroaryl;
- Z 1 and Z 2 are independently H, halogen, CN, C0 2 R,, CONR ' R,,, C! _ 4 alkyl, CJ _ 4 heteroalkyl, perfluoro C ⁇ - 4 alkyl, aryl, heteroaryl, NR, R,, or OR, '; Z 1 and Z 2 together To form a 5-, 6-, 7- or 8-membered cycloalkane, heterocycloalkane, aromatic or heteroaromatic ring; R 3 and R 4 independently represent H etc .; R ′ and R It is reported that a compound represented by '' independently represents H or the like] is useful for the prevention or treatment of inflammation by regulating an interleukin-1 receptor-related kinase (International Publication No. 03 (See / 030902 pamphlet).
- An object of the present invention is to provide a GPR40 receptor function regulator useful as an agent for preventing / treating obesity, hyperinsulinemia, type 2 diabetes and the like.
- the condensed imidazole compound represented by the following formula (I) has an unexpectedly superior GPR40 receptor function regulating action, It was found useful as a preventive / therapeutic agent for diseases, and the present invention was completed based on these findings.
- the present invention is as follows.
- ring A represents an optionally substituted ring
- B 1 and B 2 independently represent an optionally substituted cyclic group
- R x is a hydrogen atom or substituent, n x is an integer from 0 to 2
- Y is a bond, optionally substituted C—3 alkylene group, 1 O—, 1 NR Y 1 or 1 S (O) ⁇ ⁇ — (R Y is a hydrogen atom or substituent, ⁇ ⁇ is 0 Or an integer of 2).
- the agent according to the above (1) which is a physiological function regulator involving the GPR40 receptor or a preventive / therapeutic agent for a disease state or disease involving the GPR40 receptor.
- the agent according to (1) above which is an insulin secretion regulator, a knee protectant, or an insulin resistance improver.
- the agent according to (1) which is a prophylactic / therapeutic agent for infarction, thrombotic disease, memory learning disorder, manic depression, visual impairment, appetite regulation disorder, lipotoxicity, knee fatigue, immune system disease, inflammatory disease or cancer .
- a method for regulating the function of a GPR40 receptor comprising administering an effective amount of the fused imidazole compound or a salt thereof or a prodrug thereof according to (1) to a mammal.
- ring A a represents a benzene ring substituted with a substituent excluding a nitro group and a jetylsulfamoyl group, or an optionally substituted pyridine ring, Z is CH or N,
- B a 1 represents an optionally substituted 5-membered aromatic ring group or an optionally substituted 6-membered ring group
- B a 2 represents an optionally substituted 5- to 6-membered aromatic ring group
- Xa represents one O—, one NR a— (where R a represents a hydrogen atom or an optionally substituted C- 6 alkyl group) or one S—
- Ya represents an optionally substituted 1 3 alkylene group.
- X a—Y a is not one NHCO— and B a 1 is not a substituted triazinyl group.
- (9) is a B a 1 force which may be substituted phenyl group, (7) compounds of described.
- the substituent is selected from an optionally substituted Ci-s alkyl group, an optionally substituted 6 alkoxy group, a C- 6 alkoxy-carbonyl group, and a 6 alkyl carbonyl group.
- Substituents may be halogenated or halogenated C- 6 alkyl
- a medicament comprising the compound according to (7) or a prodrug thereof.
- a method for antagonizing a GPR40 receptor comprising administering an effective amount of a non-peptide nitrogen-containing heterocyclic compound to a mammal.
- the GPR 40 receptor function regulator of the present invention is useful as a prophylactic / therapeutic agent for obesity, hyperinsulinemia, type 2 diabetes and the like.
- the “halogen atom” in the present specification includes a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- the “optionally substituted hydrocarbon group” in the present specification unless otherwise specified, for example, “optionally substituted C i _ 6 alkyl group”, “optionally substituted C 2 one 6 Arukeeru group:] "optionally substituted C 2 - 6 alkynyl group”, “optionally substituted C 3 - 8 cycloalkyl group”, “optionally substituted C 6 - 4 Aryl group ”,“ optionally substituted C 7 —i 6 aralkyl group ”and the like.
- C i 6 alkyl group unless otherwise specified, for example, methyl, Echinore, Puropinore, isopropylidene Honoré, Buchinore, Isopuchinore, sec one Petit Honoré, tert one heptyl, Penchinore, Isopenchinore, Neopentyl, hexinole and the like.
- C 2 6 alkynyl group for example, Echininore, Purono ⁇ 0 Noreginore, 1 one Puropininore, 2-leptin one 1 Inore, 4-Bae Nchin one 1 one ⁇ f, 5-hexyne 1-yl and the like.
- C 3 _ 8 cycloalkyl group in the present specification, unless otherwise specified, for example, Shikuropuropinore, Shikuropuchiru, cyclopentyl, cyclohexyl and the like cyclohexylene.
- C 6 4 Ariru group for example, phenyl, 1 one naphthyl, 2-naphthyl, 2-Bifue two Lil, 3 Bifue two Lil, 4 Bifue two Ril, 2-anthryl and the like.
- the C 6 — 4 aryl may be partially saturated, and partially saturated C 6 —!
- Examples of 4 aryl include tetrahydranaphthyl and the like.
- Examples of the C 6 — aryl group also include groups derived from a condensed ring of “aromatic hydrocarbon” described later and “alicyclic hydrocarbon” described later. For example, indanyl, indur, fluorenyl, etc.
- C 3 one 6 Arukeniruokishi group in the present specification, unless otherwise specified.
- Ariruokishi 2-heptene one 1 one Iruokishi, 4-pentenoic one 1 Iru Okishi, hexene one 1 to 5 And yloxy.
- cycloalkyl O alkoxy group for example, cyclopropyl O alkoxy, cycloalkyl Petit Ruo alkoxy, Shikuropenchiruo alkoxy, Kishiruokishi etc. cyclohexylene.
- heterocyclic oxy group examples include a hydroxy group substituted with a “heterocyclic group” described later.
- the heterocyclic oxy group include tetrahydroxy-loxy, thiazolyl-oxy, pyridyloxy, virazolyloxy, oxazolyloxy, cheniloxy, furyloxy and the like.
- examples of the “C 6 —i 4 aryloxy group” in the present specification include phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like.
- examples of the “C 7 _ 1 6 Ararukiruokishi group” in the present specification otherwise stated no limit is, for example, Benjiruokishi, Fuenechiruokishi, 9 one full O Les methylpropenylmethyl O key sheet, and the like.
- examples of the “d- 6 alkyl monocarbonyloxy group” in the present specification include acetyloxy and the like.
- examples of the “C i — 6 alkylsulfonyloxy group” in the present specification include methylsulfonyloxy, ethylsulfuroxy and the like.
- heterocyclic sulfooxy group examples include a sulfonyloxy group substituted with a “heterocyclic group” described later.
- heterocyclic sulfonyloxy group examples include cenylsulfonyloxy, furylsulfo-oxy and the like.
- examples of the “optionally substituted mercapto group” in the present specification include “mercapto group”, “optionally substituted — 6 alkylthio group”, and “substituted”. which may be c 3 - 6 alkenylthio group ",” optionally substituted C 3 one 6 alkynylthio group ",” optionally substituted C 3 - 8 consequent Roarukiruchio group ",” substituted also heterocyclic Chio group ",” optionally substituted C 6 - 1 4 Ariruchio group ",” optionally substituted C 7 - i 6 ⁇ la alkylthio group "and the like.
- ⁇ - 6 alkylthio group means, for example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, unless otherwise specified. And isobutylthio, sec-butylthio, tert-butylthio and the like.
- C 3 6 alkenylthio group unless otherwise specified, for example, Ariruchio, 2-butene, down one 1 Iruchio, 4-pentenoic one 1 Iruchio,
- C 3 _ 6 alkynylthio group in the present specification, unless otherwise specified, for example, propargylthio, 2-butyn one 1- Iruchio, 4 one pentyne one 1 one ⁇ f thio, the 5-connexin 1 1-ilthio.
- C 3 _ 8 cycloalkylthio group in the present specification, otherwise stated no limit is, for example, cyclopropylthio, cycloalkyl Petit Lucio, cyclopentylthio, cyclohexylthio, and the like cyclo.
- heterocyclic thio group examples include a mercapto group substituted with a “heterocyclic group” described later.
- heterocyclic thio group examples include tetrahydropyranylthio, thiazolylthio, pyridylthio, virazolylthio, oxazolylthio, chelthio, furylthio and the like.
- C 6 —i 4 arylthio group includes, for example, phenylthio, 1-naphthylthio, 2-naphthylthio and the like, unless otherwise specified.
- C 7 6 Ararukiruchio group in the present specification, for example, benzylthio, Fuenechiruchio and the like.
- heterocyclic group as a ring constituent atom, one or two kinds selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to a carbon atom, 1 3 to 4 members containing 4 heteroatoms (monocyclic, bicyclic or
- Tricyclic heterocyclic group preferably (i) 5- to 14-membered (preferably 5- to 10-membered) aromatic heterocyclic group, (ii) 3- to 10-membered non-aromatic heterocyclic group, etc. It is done. Of these, a 5- or 6-membered aromatic heterocyclic group is preferred.
- the nitrogen atom and sulfur atom as the ring constituent atoms may be oxidized to N-oxide, S-oxide, S, S-dioxide.
- heterocyclic group examples include, for example, cenyl (eg, 2-chenyl, 3 ), Furyl (eg, 2-furyl, 3-furyl), thiazolyl (eg, 2-thiazolyl, 41-thiazolyl, 5-thiazolyl), oxazolyl (eg, 2-oxazolyl, 4-oxazolyl,, 5— Oxazolyl), pyrrolyl (eg, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (eg: 1 imidazolyl, 2 f imidazolyl, 4 imidazolyl), pyrazolyl (eg: 1 monopyrazolyl, 3-pyrazolyl, 4-monopyrazolyl), isothiazolinol (eg 3-isothiazolyl, 4-monoisothiazolyl, 5- ⁇ f sothiazolyl), isoxazolyl (eg 3-isoxazolyl,
- Pyridyl eg 2-pyridyl, 3-pyridyl, 4-pyridyl
- pyrazinyl e.g: 2-pyrimidinyl, 4-pyrimidinyl
- pyridazinyl eg: 3-pyridazinyl, 4-pyridazinyl
- Quinolyl eg, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl
- isoquinolyl eg, 1 f soquinolyl, 3-isoquinolyl, 4-1 isoquinolyl, 5-isoquinolyl
- quinazolinyl eg: 2-quinazolinyl, 4-quinazolinyl, 5-quinazolinyl, 6-quinazolinyl
- quinoxalinyl eg: 2-quinazolinyl, 4-quinazolinyl, 5-quinazolinyl, 6-quinazolinyl
- Oxylanyl e.g. 2-oxylur
- thiranyl e.g. 2-thiranyl
- 3-membered non-aromatic bicyclic groups such as aziridyl (eg 1-aziridiel, 2-aziridinyl); 'year-old xetaninole (eg 2-oxetul), chetanyl (eg 2-thietanyl), azetidules (eg 1 4-membered non-aromatic heterocyclic groups such as 1-zetid: ⁇ , 2-azetidur, 3-azetidul;
- Pyrrolidinyl eg: 1-pyrrolidinyl, 2-pyrrolidyl, 3-pyrrolidinyl
- oxazolidinyl eg: 2-oxazolidinyl
- thiazolidinyl eg: 2-thiazoliduryl
- imidazolyl eg: 1 imidazolidyl, 2-imidazoline 2) , 41-imidazolinyl
- dioxorael eg, 2-dioxolanyl
- oxazolyl eg, 2-oxazolinyl
- thiazoliel eg, 2-thiazolinyl
- tetrahydrofuranyl eg, 2-tetrahydrofurfuryl
- tetrahi 5-membered non-aromatic heterocyclic groups such as drochenil (eg 2-tetrahydrodrenyl); piperidur (eg 1-piperidinyl, 2-pi
- 2-Tetorahi Dorochiobiraniru di O Kisaniru (e.g. 1, 4 - Jiokisan one 2 one I le) 6-membered non-aromatic heterocyclic groups such as; Azepaniru (eg 1 one Azepa - le, 2- Azepanyl, 3-azepanyl), homopiperazinyl (eg, 1 homopiperagel, 2-homopiperadur, 5-homopiperager), 1,4-oxazepanyl (eg, 1,4-oxazepan_4 1il), 7-membered non-aromatic heterocyclic groups such as 1,4-thiazepanyl (eg, 1,4-thiazepane-4-yl);
- Azepaniru eg 1 one Azepa - le, 2- Azepanyl, 3-azepanyl
- homopiperazinyl eg, 1 homopiperagel, 2-homopiperadur, 5-homopiperager
- heterocyclic carbonyl group in the present specification include a carbonyl group substituted with the above “heterocyclic group”.
- the heterocyclic carbonyl group include furyl, tenol, pyrazolylcarbonyl, thiazolylcarbonyl, oxazolyl force ruponyl, pyridylcarbonyl, indolylcarbonyl, benzofuranylcarbonyl, benzochelylcarbonyl, quinolyl.
- Strength lupoel isoquinolylcarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, tetrahydropyranylcarbonyl and the like.
- aromatic heterocyclic carbo group examples include a carbonyl group substituted with an “aromatic heterocyclic group” among those exemplified in the above “heterocyclic group”.
- aromatic heterocyclic carbonyl group examples include furoyl, tenole, pyrazolinole force luponinole, thiazolylcarbonyl, oxazolylcarbonyl, Examples include pyridi / recazoreponole, indolinolecanoporonole, benzofuranolecanoporonole, benzocenylcarpoel, quinolylcarbonyl, and isoquinolylcarponyl. ,
- the “nitrogen-containing non-aromatic heterocyclic carbo group” is a carbonyl substituted with one of those exemplified in the above-mentioned “hetero-cyclic group” and “nitrogen-containing non-aromatic heterocyclic group” Groups.
- the nitrogen-containing non-aromatic heterocyclic carbonyl group include pyrrolidinyl polyol, piperidinyl carbonyl and the like.
- the “optionally halogenated and C ⁇ _ 6 alkyl group J in the present specification unless otherwise indicated, 1 to 5 of the above-mentioned" halogen atom "which may be substituted with the above”.
- - 6 alkyl group For example, methyl, ethyl, propinole, isopropinole, butinole, tert-butyl, isoptinore, trifanololomethyl and the like can be mentioned.
- the “optionally halogenated C i- 6 alkoxy group” in the present specification includes the above “C i” which may be substituted with 1 to 5 of the above “halogen atoms”. — 6- alkoxy group ”.
- methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2-tetrafluoroethoxy and the like can be mentioned.
- the “di- 6 alkyl sulphonyl group” in the present specification includes, for example, acetyl, isoptanol, and isopentanoyl.
- C 3 8 cycloalkyl one carbonyl group for example, cyclopropylcarbonyl, cyclopropyl cycloheptyl carbonyl, shea click opening pliers Luca Lupo alkenyl, Kishirukaruponiru like to consequent opening .
- examples of the “C 6 —i 4 aryl monocarbonyl group” in this specification include benzoyl, 1-naphthoyl, 2-naphthoyl and the like.
- examples of the “C 7 —i 6 aralkyl first force sulfonyl group” in the present specification include phenylacetyl, 2-phenylpropanoyl and the like.
- examples of the “C i- 6 alkoxy monocarbonyl group” in the present specification include methoxycarbonyl, ethoxycarbonyl, propoxycarbo binole, tert monobutoxy, bonyl and the like.
- C 7 —i 6 aralkyloxycarbonyl includes, for example, benzyl / leoxycarboninole, phenethyloxycarbonyl, 9 monofluorenylmethyloxycarbonyl, unless otherwise specified. Etc.
- ji- 6 alkylsulfonyl group includes, for example, methylsulfonyl, ethylsulfonyl and the like, unless otherwise specified.
- C 6 _i 4 arylsulfonyl group examples include, unless otherwise specified, for example, phenyl norephonol, 1-naphthyl norenoyl, 2-naphthyl / resulfur, etc. .
- O- 6 alkylsulfier group includes, for example, methyls / refyr, ethylsulfinyl, and the like, unless otherwise specified.
- C 6 4 ⁇ reel sulfinyl group in particular system unless otherwise stated, for example, Hue Nils sulfide El, 1 one naphthylsulfide El, 2-naphthoquinone Chirusurufiniru the like.
- the “mono- or di-C i — 6 alkyl monostrength rubamoyl group” refers to a mono- or di-monosubstituted rubamoyl group substituted with the above “C i — 6 alkyl group”.
- Examples thereof include methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, jetylcarbamoyl, ethylmethylcarbamoyl and the like.
- the “c 7 — 1 6 aralkyl one-strength rubermoyl group” in the present specification includes a force ruberamoyl group mono-substituted by the above “C 7 —! 6 aralkyl”.
- benzylcarbamoyl etc. are mentioned.
- the term “mono- or di-C 6 14- aryl sulfamoyl group” in this specification refers to a sulfamoyl mono- or di-substituted with the above “c 6 —i 4- aryl group”. Examples thereof include phenylsulfamoyl, diphenylsulfamoyl, 1-naphthylsulfamoyl, 2-naphthylsulfamoyl and the like.
- the “mono- or di-monoalkyl-6amino group” in the present specification includes an amino group mono- or disubstituted with the above “C- 6 alkyl group”. Examples include methylamino, ethylamino, propylamino, dimethylamino, and jetylamino.
- mono- or di-one C 7 - J 6 ⁇ Lal kills over ⁇ amino group include, unless otherwise specified, the - is mono- or di-monosubstituted with "C 7 i 6 Ararukiru group” And an amino group.
- benzylamino, phenethylamino and the like can be mentioned.
- N—— 6 alkyl 1 N—C 6 14 1 arylamine group in the present specification includes the above “C i — 6 alkyl group” and the above “C 6 — 4 aryl”. And an amino group di-substituted by.
- N-methyl-N-phenylamino, N-ethyl-1-N-phenylamino and the like can be mentioned.
- N-_ 6 alkyl one N- C 7 -! 6 ⁇ Lal kills over ⁇ amino group include, unless otherwise noted, the re - 6 alkyl group "and the" C 7 6 Ararukiru And an amino group disubstituted by “group”.
- group N-methyl-1-N-benzylamino, N-ethyl-N-benzylamino and the like can be mentioned.
- Halogen atom, hydroxyl group, amino group, nitro group, cyano group, optionally halogenated _ 6 alkyl group, optionally halogenated Ci 16 alkoxy group, d 16 alkylthio group and 1 a stone 3 substituents in the optionally substituted C 6 one also be 1 4 Ariru group selected from a carboxyl group;
- halogenated one may 6 Arukinore group, halogenated which may be C i _ 6 alkoxy group, d one 6 alkylthio group
- a heterocyclic group optionally substituted with 1 or 3 substituents selected from an opi-carboxyl group (preferably furyl, phenyl, pyrazolyl, thiazolyl, oxazolyl, pyridyl);
- Halogen atom, hydroxyl group, amino group, nitro group, cyano group may be halogenated ⁇ 6 alkyl group, optionally halogenated C ⁇
- Halogen atom, hydroxyl group, amino group, nitro group, cyano group, optionally halogenated 16 alkyl group, optionally halogenated C ⁇ _ 6 alkoxy group, C chi _ 6 alkylthio to 1 selected from group and a carboxyl group 3 may be substituted with a substituent C 7 - J 6 Ararukiruokishi group;
- halogen atom arsenic Dorokishi group, an amino group, a nitro group, Shiano group, halogen of which may be optionally _ 6
- Anorekinore group one that may be halogenated
- Yopi 1 selected from carboxyl group to three optionally substituted with optionally substituted heterocyclic Karuboyuru group (preferably full Royle, Tenoiru, Vila sledding Luca Lupo sulfonyl, thiazolyl Carbonyl, oxazolylcarbonyl, pyridylcarbonyl);
- Optionally substituted heterocyclic Suruhoniruokishi group "optionally substituted C 3 - 8 cycloalkylthio group”, “optionally substituted heterocyclic Chio group”, "substituted Examples of good C 6 1 1 4 arylthio group ”,“ optionally substituted C 7 _! 6 aralkylthio group ”and“ optionally substituted heterocyclic group ”include, for example,
- a halogen atom, arsenic Dorokishi group, an amino group, a nitro group, Shiano group may be halogenated - 6 alkyl group, optionally halogenated C _ 6 alkoxy group, d _ 6 alkylthio group and optionally substituted with one stone 3 substituents selected from carboxyl group C 6 - 1 4 Ariru group;
- Halogen atom, hydroxyl group, amino group, nitro group, cyano group may be halogenated — 6 alkyl group, optionally halogenated — 6 alkoxy group, d_6 alkylthio group and carboxyl
- a heterocyclic group optionally substituted with 1 or 3 substituents selected from a group (preferably furyl, phenyl, pyrazolyl, thiazolyl, oxazolyl, pyridyl); (10) optionally substituted— 6 alkoxy groups;
- a C 6 _ 1 ⁇ aryloxy group optionally substituted with 1 to 3 substituents selected from a 6 alkoxy group, a Ci _ 6 alkylthio group and a carboxyl group;
- a heterocyclic carbonyl group optionally substituted with 1 to 3 substituents selected from a 6 alkoxy group, a 6 alkylthio group and a carboxyl group (preferably furoyl, tenol, pyrazolylcanoleponyl, thiazolylcarbonyl, Oxazoli Norecano Reboninore, Pyridinole Power / Repo Nonore);
- the “optionally substituted acyl group” in the present specification is represented by the formula: — COR 1 — CO— OR 1 , —S0 2 R 1 N — S OR 1 , 1 PO ( OR 1 ) (OR 2 ), -CO-NR 1 a R 2 a , -CS -NR 1 a R 2 a or one S0 2 -NR 1 a R 2 a wherein R 1 and R 2 are the same Or differently represents a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R 1 a and R 2 a are the same or different, a hydrogen atom, substituted Represents an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted hydroxy group, or R 1 a and R 2 a may be substituted together with the adjacent nitrogen atom. And may form a good nitrogen-containing heterocycle].
- nitrogen-containing heterocycle in the “optionally substituted nitrogen-containing heterocycle” formed by R 1 a and R 2 a together with the adjacent nitrogen atom, for example, as a ring-constituting atom, in addition to the carbon atom It contains at least one nitrogen atom, and may further contain 1 to 2 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms. It is done.
- the nitrogen-containing heterocycle include pyrrolidine, imidazolidine, virazolidine, thiazolidine, oxazolidin, piperidine, piperazine, morpholine, thiomorpholine and the like.
- the nitrogen-containing heterocycle may have 1 to 2 substituents at substitutable positions. Yes. Examples of such a substituent include a hydroxyl group and an optionally halogenated C.
- ! - 6 alkyl group may be halogenated - 6 alkoxy group, C 6 - chi 4 Ariru group, C 7 - 6 Ararukiru group.
- Ci- 6 alkoxy group which may be substituted
- an optionally substituted heterocyclic group preferably furyl, pyridyl, chenyl, pyrazolyl, thiazolyl, oxazolyl
- nitrogen-containing heterocycle includes, for example, at least one nitrogen atom in addition to a carbon atom as a ring-constituting atom, and further 1 to 2 atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom. Examples include 5- to 7-membered nitrogen-containing heterocycles that may contain a terror atom.
- nitrogen-containing heterocycle examples include pyrrolidine, imidazolidine, virazolidine, thiazolidine, oxazolidin, piperidine, piperazine, morpholine, thiomorpholine and the like.
- NC! - 6 alkyl one N-C 7 one 6 ⁇ Lal kills over ⁇ amino group;
- NC i _ 6 alkyl one ⁇ - - 6 alkyl one carbonylation Ruamino group
- the “Ci 1-3 alkylene group” in the “optionally substituted C 1-3 alkylene group” in this specification may be either linear or branched, such as methylene, methenolemethylene, dimethyl. Examples include nolemethylene, ethylene, 1-methyl / reethylene 2-methylethylene, and the like.
- the Ji 1 - 3 alkylene group, a substitutable position may have 1 to 3 substituents. Examples of such substituents include:
- Aromatic heterocyclic carbonyl group eg, pyridylcarbol. Furoyl, tenol, indolylcarbonyl
- ring A represents an optionally substituted ring.
- the “ring” in the “optionally substituted ring” is, for example, an aromatic ring such as an aromatic hydrocarbon or an aromatic heterocyclic ring; a non-cyclic ring such as an alicyclic hydrocarbon or a non-aromatic heterocyclic ring.
- an aromatic ring is mentioned.
- aromatic hydrocarbons examples include aromatic hydrocarbons having 6 to 14 carbon atoms.
- aromatic hydrocarbons include benzene, naphthalene, anthracene, phenanthrene, and acenaphthylene.
- aromatic heterocycle examples include, for example, a 5- to 7-membered monocyclic aromatic group containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms as ring constituent atoms.
- Group heterocycle or condensed aromatic heterocycle examples include these 5- to 7-membered monocyclic aromatic heterocycles, 6-membered rings containing 1 or 2 nitrogen atoms, benzene rings, or 1 sulfur atom. And a ring condensed with a 5-membered ring.
- aromatic heterocycle examples include furan, thiophene, pyrrole, imidazole, pyrazole, isoxazonorole, isothiazole, oxazole, thiazo mononole, 1, 2, 3-oxadiazo monole, 1, Monocyclic aromatic heterocycles such as 2,3-thiadiazonole, 1,2,3-triazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine;
- Examples thereof include condensed aromatic heterocycles such as 1 H-imidazopyridine, 1 H-imidazopyrazine, isoquinoline, and benzothiadiazole.
- alicyclic hydrocarbon examples include saturated or unsaturated alicyclic hydrocarbons having 3 to 12 carbon atoms, such as cycloalkane, cycloalkene, and cycloalkadiene.
- cycloalkanes having 3 to 10 carbon atoms, such as For example, cycloprono, , Cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, bicyclo [2. 2. 1] heptane, bicyclo [2, 2. 2] octane, bicyclo [, 3. 2. 1] octane, bicyclo [ 3. 2. 2] Nonane, bicyclo [3. 3.1] nonane, bicyclo [4.2.1] nonane, bicyclo [4.3.1] decane.
- cycloalkene examples include cycloalkene having 4 to 10 carbon atoms, such as cyclobutene, cyclopentene, cyclohexene and the like.
- cycloa ⁇ -cadiene examples include cycloacadiens having 4 to 10 carbon atoms such as 2,4-cyclopentagen, 2,4-cyclohexagen, 2,5-cyclohexagen and the like. .
- Non-aromatic heterocycles include, for example, 5 to 7-membered monocyclic ring containing 1 to 4 heteroatoms selected from oxygen atom, sulfur atom and nitrogen atom in addition to carbon atom
- Non-aromatic heterocycles or fused non-aromatic heterocycles can be mentioned.
- fused non-aromatic heterocycle include, for example, these 5- to 7-membered monocyclic non-aromatic heterocycles, 6-membered rings containing 1 to 2 nitrogen atoms, benzene rings, or 1 sulfur atom. And a ring condensed with a 5-membered ring containing.
- non-aromatic heterocycle examples include pyrrolidine, pyrroline, virazolidine, oxazolidine, thiazolidine, imidazolidine, imidazoline, tetrahydrofuran, piperidine, piperazine, monoreforin, thiomonoreforin, hexamethyrenimine (azepane), And monocyclic non-aromatic heterocycles such as tetrahydropyridine; benzene ring-fused non-aromatic heterocycles such as dihydrobenzofuran.
- an aromatic ring is preferable, and a benzene ring and a pyridine ring are more preferable.
- the “ring” in the “optionally substituted ring” represented by ring ⁇ may have, for example, 1 to 5, preferably 1 to 3 substituents at substitutable positions. .
- substituted examples include a halogen atom, a nitro group, a cyano group, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group, and an optionally substituted group.
- substituents include a good mercapto group, an optionally substituted heterocyclic group, an optionally substituted acyl group, and an optionally substituted amino group.
- each substituent may be the same or different.
- Ring A is preferably a benzene ring substituted with the above substituent or a pyridine ring, and more preferably a benzene ring substituted with 1 to 3 halogen atoms.
- B 1 and B 2 each independently represent a cyclic group that may be substituted.
- the "cyclic group" in the "optionally substituted cyclic group” includes, for example if, C 3 - 8 cycloalkyl group, C 6 - i 4 Ariru group, Ru heterocyclic group and the like. Of these, a cyclohexyl group, a phenyl group, a pyridyl group, a piperidinyl group, a dihydrobenzo [b] furanyl group and the like are preferable.
- B 1 is preferably a phenyl group which may be substituted, and more preferably a phenyl group having a substituent at the para position.
- B 2 is preferably an optionally substituted phenyl group or an optionally substituted pyridyl group, more preferably a vinyl group having a substituent at the para position or a substituent at the 6 position. 3-Pyridyl group.
- the “cyclic group” in the “optionally substituted cyclic group” represented by B 1 or B 2 has, for example, 1 to 5, preferably 1 to 3 substituents at substitutable positions. It may be.
- substituent the “substituted” represented by the above ring A Examples of the substituent that the “ring” in the “optional ring” may have are listed.
- each substituent may be the same or different.
- Ci one 6 alkyl group preferably a halogen atom, arsenic Dorokishi group, - 6 alkoxy groups, C 6 - E 4 Ariruokishi group, carboxyl group, C alpha _ 6 alkoxy one carbonyl group, CJ _ 6 alkyl one Karuboeruoki shea group, optionally substituted by 1 to selected from C 3 _ 8 cycloalkyl group 4 substituents C - 6 alkyl group);
- substituted one may 6 alkoxy group (preferably a halogen atom, arsenic Dorokishi group, - 6 alkoxy groups, C 6 - 4 Ariruokishi group, carboxyl group, - 6 alkoxy one carbonyl group, - 6 alkyl one Karuboniruo alkoxy group, an optionally substituted to 1 selected from C 3 _ 8 cycloalkyl group with 4 substituents Ci - 6 alkoxy groups);
- 6 alkoxy group preferably a halogen atom, arsenic Dorokishi group, - 6 alkoxy groups, C 6 - 4 Ariruokishi group, carboxyl group, - 6 alkoxy one carbonyl group, - 6 alkyl one Karuboniruo alkoxy group, an optionally substituted to 1 selected from C 3 _ 8 cycloalkyl group with 4 substituents Ci - 6 alkoxy groups
- heterocyclic group preferably oxazolinyl, oxazolyl, dioxolane
- substituents in B 1 represents, optionally substituted - 6 alkyl group, optionally substituted - 6 alkoxy group, - 6 alkoxy Ichiriki Ruponiru groups and C - 6 alkyl one
- the carbonyl group is selected, and the substituent in B 2 is selected from a halogen atom or an optionally halogenated Ci 16 alkyl group.
- X represents an optionally substituted C—3 aralkylene group, 1 O—, 1 NR X —or 1 S (O) n x —
- R x represents a hydrogen atom or a substituent, n x represents 0 or an integer of 2.
- the “optionally substituted 1 3 alkylene group” represented by X is preferably a methylene group.
- R x As the "substituent" represented by R x, for example, it may be substituted - 6 alkyl group, a formyl group, - 6 alkyl - carbonyl group, C 1 _ 6 alkoxy Sea carbonyl group, C 7 _ 6 Ararukiru one Karuboeru group, C 6 - 4 Ariru Okishi one carbonyl group, C 7 - 6 Ararukiruokishi Ichiriki Lupo - le group, and the like et be.
- R x is preferably a hydrogen atom.
- nx is preferably 0.
- X is preferably 1 S— or 1 NH—.
- Y is a bond, an optionally substituted _ 3 alkylene group, 1 O—, 1 NR Y — or 1 S (O) ⁇ ⁇ — (R Y is a hydrogen atom or a substituent ⁇ ⁇ represents an integer of 0 to 2).
- the “optionally substituted Ci-3 alkylene group” represented by Y is preferably
- Aromatic heterocyclic force lupoel group (preferably indolyl force luponyl)
- R Y examples include those exemplified as R x .
- R Y is preferably a hydrogen atom.
- ⁇ ⁇ is preferably 0.
- ⁇ is preferably an optionally substituted- 3 alkylene group or 1-O-, more preferably a methylene group.
- Compound (I) is preferably compound (I I).
- ring A a is a substituted benzene ring (wherein the substituent of the benzene ring is not a nitro group or a jetylsulfamoyl group), or an optionally substituted pyridine ring. Show.
- examples of the substituent in the benzene ring and the pyridine ring are examples of the substituent that the “ring” in the “optionally substituted ring” represented by the ring A in the formula (I) may have. The thing which was done is mentioned.
- the number of substituents is, for example, 1 to 5, preferably 1 to 3.
- Ring A a is preferably
- Z represents CH or N, preferably CH.
- B a 1 represents an optionally substituted 5-membered aromatic ring group or an optionally substituted 6-membered ring group.
- examples of the “5-membered aromatic ring group” in the “optionally substituted 5-membered aromatic ring group” include 5-membered aromatic heterocyclic groups exemplified as the “heterocyclic group” and the like. .
- a cyclohexyl group, a phenyl group, a pyridyl group, a piperidinyl group and the like are preferable.
- B a 1 is preferably an optionally substituted phenyl group, and more preferably a phenyl group having a substituent at the para position.
- “5-membered aromatic ring group” in “optionally substituted 5-membered aromatic ring group” and “6-membered ring group” in “optionally substituted 6-membered ring group” are in the substitutable position. For example, it may have 1 to 5, preferably 1 to 3 substituents.
- substituents include those exemplified as the substituent that the “ring” in the “optionally substituted ring” represented by the ring A in the formula (I) may have.
- — 6 alkyl group preferably halogen atom, hydroxy group, — 6 alkoxy group, C 6 ⁇ 4 aryloxy group, carboxyl group, C 6 alkoxy-carbonyl group, — 6 alkyl group Rupoyuruokishi group, to 1 selected from C 3 ⁇ 8 cycloalkyl group substituted with four substituents Optionally 6 alkyl groups);
- — 6 alkoxy group preferably a halogen atom, a hydroxyl group, — 6 alkoxy group, C 6 — i 4 aryloxy group, a carboxylate group, C! _6 ananoloxycarbonyl group, C ! _ 6 Anorekiru Ichiriki Noreboninore old alkoxy group, C 3 - 8 cycloalkyl 1 to 4 may be substituted with a substituent C ⁇ _ 6 alkoxy group selected from the group);
- heterocyclic group preferably oxazolinyl, oxazolyl, dioxoral
- Etc Preferably, optionally substituted Ci one even though 6 alkyl group, optionally substituted - 6 alkoxy group, - 6 alkoxy one Karuponiru group Contact and C - selected from Karuponiru group - 6 alkyl.
- B a 2 represents an optionally substituted 5- to 6-membered aromatic ring group.
- the “5-membered aromatic ring group” in the “optionally substituted 5- to 6-membered aromatic ring group” include the “5-membered aromatic heterocyclic group exemplified as the heterocyclic group” and the like.
- the “6-membered aromatic ring group” in the “optionally substituted 5- to 6-membered aromatic ring group” include a phenyl group, the 6-membered aromatic heterocyclic group exemplified as the above-mentioned “heterocyclic group”, and the like.
- ⁇ can be mentioned among others, off group, 6-membered aromatic Hajime Tamaki (preferred properly pyridyl group) are preferable.
- B a 2 is preferably an optionally substituted phenyl group or an optionally substituted pyridyl group, more preferably a fuel group having a substituent at the para position or a 3-pyridyl having a substituent at the 6 position. It is a group.
- the “5- to 6-membered aromatic ring group” in the “optionally substituted 5- to 6-membered aromatic ring group” means, for example, 1 to 5, preferably 1 to 3 positions at substitutable positions. Each may have a substituent.
- substituents include those exemplified as the substituent which the “ring” in the “optionally substituted ring” represented by ring A in formula (I) may have.
- substituted one may 6 alkyl group (preferably a halogen atom, arsenic Dorokishi group, - 6 alkoxy groups, C 6 4 Ariruokishi group, carboxyl group, - 6 alkoxy - carbonyl group, C i 6 alkyl one carbonylation Ruoki sheet group may be substituted with 1 to 4 substituents selected from C 3 8 cycloalkyl group, - 6 alkyl group);
- optionally substituted — 6 alkoxy group (preferably a halogen atom, a hydroxy group, — 6 alkoxy group, C 6 — i 4 aryloxy group, carboxy group, — 6 alkoxy allyl group, — Substituted with 1 to 4 substituents selected from 6 alkyl monocarbonyloxy groups, C 3 8 cycloalkyl groups, etc.
- Etc Preferably selected from optionally C 1 _ 6 alkyl group which may be halogen atoms and halogenated.
- X a represents 1 O—, 1 NR a— (R a represents a hydrogen atom or an optionally substituted 6- alkyl group) or 1 S—.
- R a is preferably a hydrogen atom.
- X a is preferably _S— or 1 NH—.
- Y a represents an optionally substituted —3 alkylene group. Y a is preferably
- aromatic heterocyclic carbonyl group (preferably indolylcarbonyl);
- X a—Y a is not one NHCO— and B a 1 is not a substituted triazinyl group.
- Compound (II) is also composed of 2- (benzylthio) 1 5-chloro 1-phenyl-1 H-benzimidazole and 2- (2-chloro benzyl regio) — 5-chloro 1 1 phenol.
- 1 H Excludes Benzymidazo 1 / Le.
- compound (II) is 1- (4-tert-Iptinololefinore) 1-Methoxycanoleponinole 2— [(4-Metoxenoreponinorevenginole) thio] 1 1 H-benzimidazole,
- compound (I I) include the following compounds.
- Z is C H
- a halogen atom arsenic Dorokishi group, - 6 alkoxy group, a force Rupokishiru group, C 1 _ 6 alkoxy one carbonyl group, CJ _ 6 alkyl one Karuponiruokishi group, C 3 - 8 1 to 3 selected from cycloalkyl group Substituted with a substituent of C-6 alkoxy group;
- a phenyl group or a pyridyl group each optionally having 1 to 3 substituents selected from
- Aromatic heterocyclic carbo group (preferably indolylcarbonyl); each may have 1 or 2 substituents selected from such as methylene group or ethylene group (Ya is preferably methylene Group);
- An optionally substituted _ 6 alkyl group (preferably a halogen atom, a hydroxy group, — 6 alkoxy group, C 6 — i 4 aryloxy group, carboxyl group, — 6 alkoxy monocarbonyl group, — 6 alkyl - carbonylation Ruoki shea group and C 3 - 8 cycloalkyl 1 selected from groups to four which may be C E replaced by a substituent - 6 alkyl group);
- — 6 alkoxy group preferably a halogen atom, Hydroxy group, — 6 alkoxy group, c 6 — t 4 aryloxy group, carboxy group, C i — 6 alkoxy group, sulfonyl group, C! _ 6 alkyl - force Ruponiruo alkoxy group and C 3 - 8 to 1 is selected from cycloalkyl of 4 substituents may be substitution - 6 alkoxy group);
- substituted one may 6 alkyl group (preferably a halogen atom, arsenic Dorokishi group, - 6 alkoxy groups, C 6 _ 4 Ariruokishi group, Karupokishi group, - 6 alkoxy Ichiriki Ruponiru group, Ci - 6 Alkyl-carbonyloxy
- a C- 6 alkyl group which may be substituted with 1 to 4 substituents selected from the group C and C 3 cycloalkyl group;
- -. 6 alkoxy group preferably a halogen atom, arsenic Dorokishi group, - 6 alkoxy groups, C 6 - 4 Ariruokishi group, carboxyl group, - 6 alkoxy one carbo - Honoré group, Ci - 6 alkyl - Karuboeruo alkoxy group and C 3 one a cycloalkyl to 1 selected from groups which may be replacement by 4 substituents C i - 6 alkoxy group);
- a vinyl group or a pyridyl group each of which may be substituted with 1 to 3 substituents selected from:
- X a is S—or one NH—
- Z is C H
- An optionally substituted — 6 alkyl group (preferably a halogen atom, a hydroxy group, — 6 alkoxy group, C 6 — 4 aryloxy group, carboxyl group, C — 6 alkoxy-carbonyl group, C ⁇ 6 alkyl Ichiriki Ruponinoreoki shea group and C 3 - 8 to 1 is selected from cycloalkyl groups may be substituted with 4 substituents - 6 alkyl group);
- substituted one may 6 alkoxy group (preferably a halogen atom, arsenic Dorokishi group, C - 6 alkoxy group, C 6 - 4 Ariruokishi group, carboxyl group, CJ one 6 alkoxy one carbonyl group, CJ one 6 alkyl one Karuboniruo alkoxy group and C 3 - 8 cycloalkyl to 1 selected from groups which may be replacement by 4 substituents C i - 6 alkoxy group);
- X a is one S— or one NH—
- Y a is a methylene group
- the metal salt include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt, magnesium salt and barium salt; aluminum salt and the like.
- salt with an organic base examples include trimethylamine, triethylamine, pyridine, picoline, 2,6-zoretidine, ethanolanolamine, diethananolamine, triethanolanolamine, cyclohexenoreamin, dicyclo Hexylamine,
- Suitable examples of salts with inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc. And the salt.
- salts with organic acids include formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, succinic acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfone And salts with acid, p-toluenesulfonic acid and the like.
- salts with basic amino acids include salts with arginine, lysine, orthine and the like
- salts with acidic amino acids include salts with aspartic acid, glutamic acid and the like. It is done.
- pharmaceutically acceptable salts are preferable.
- a prodrug of compound (I) is a compound that is converted to compound (I) by a reaction with an enzyme, gastric acid, or the like under physiological conditions in the living body, that is, a compound (I) that undergoes oxidation, reduction, hydrolysis, etc. enzymatically. ), A compound that undergoes hydrolysis or the like due to gastric acid or the like and changes to compound (I).
- a prodrug of the compound (I) a compound in which the amino group of the compound (I) is acylated, alkylated or phosphorylated (for example, the amino group of the compound (I) is eicosanylated, alanylated, pentylamino.
- the carboxy group of the compound (I) is methyl, ethyl, tert, A compound esterified with a Ci- 6 alkyl group such as butyl is preferred.
- These compounds can be produced from compound (I) force by a method known per se.
- prodrugs of Compound (I) can be obtained under the physiological conditions described in Hirokawa Shoten 1 990 “Development of Drugs”, 7th Molecular Design, 1 63 pages to 1 98 pages. It may change to.
- Compound (I) can be produced by the production method of compound (I I) described in detail below or a method analogous thereto.
- each symbol of the compound in the schematic diagram in the following reaction formula is as defined above.
- Each compound described in the reaction formula may form a salt as long as it does not inhibit the reaction. Examples of such a salt include the same salts as those in the compound (I).
- Compound (I I) can be produced, for example, by the method shown in the following reaction formula.
- the target product obtained in each of the following production methods is known separation and purification means, for example, For example, it can be isolated and purified by concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography, etc.
- the synthetic intermediate may be isolated and purified by a known separation and purification means, or may be used as a reaction mixture in the next step without isolation and purification. Good.
- Compound (I I) can be produced, for example, by the following [Method A] to [Method C] or a method analogous thereto.
- Compound (I I) can be produced, for example, by reacting compound (2a-1) with compound (2a-2).
- a halogen atom eg, chlorine, bromine, iodine
- an optionally halogenated d- 6 alkylsulfonyloxy group eg, methylsulfonyloxy, ethyl) Sulfonyloxy, trifluoromethinolesnoreoxy
- — 6 C 6 _ optionally substituted with an alkyl group!
- Aryl sunorephoninoreoxy group eg, benzene senorephoninoreoxy, 4-tonoleensenorephoninoreoxy
- methylthio group methanesulfonyl group and the like.
- This reaction can be performed in a solvent that does not adversely influence the reaction and, if necessary, in the presence of a base.
- solvents that do not adversely affect the reaction include alcohol solvents (eg, methanol, ethanol, isopropanol), ether solvents (eg, jetyl ether, tetrahydrofuran, dioxane), hydrocarbon solvents (eg, benzene, Toluene, hexane, heptane), 7 , halogenated hydrocarbon solvents (eg, dichloromethane, dichloroethane, black form, carbon tetrachloride), ketone solvents (eg, , 2-butanone), nitrile solvents (eg, acetonitrile), amide solvents (eg, dimethylformamide), ester solvents (eg, methyl acetate, ethyl acetate), etc. .
- alcohol solvents, ether solvents, hydrocarbon solvents, halogenated hydrocarbon solvents, and amide solvents are preferred. Two or more of these solvents may be mixed at an appropriate ratio
- the amount of compound (2a-2) to be used is generally 1-20 molar equivalents, preferably 1-10 molar equivalents, per 1 mol of compound (2a-l).
- the base examples include alkali metal hydrides such as sodium hydride; alkali metal carbonates such as potassium carbonate and sodium carbonate; alkali metal hydroxides such as hydroxide power sodium and sodium hydroxide; tertiary such as triethylamine.
- An amine or the like can be used.
- the amount of the base to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2a-l).
- the reaction temperature is usually from 1 to 180 ° C, preferably from 0 to 140 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the compound (2a-l) used as the raw material compound can be produced by [Method D], [Method E] or [Method F] described later.
- the compound (2a-2) used as the raw material compound can be produced by a method known per se.
- the compound (I I a) in which X a is S can be produced, for example, by reacting the compound (2 b-1) with the compound (2 b-2).
- w is a leaving group, and other symbols are as defined above.
- Examples of the leaving group represented by w include a halogen atom (eg, chlorine, bromine, iodine), an optionally halogenated ci- 6 alkylsulfonyloxy group (eg, methinolesnorephoninoreoxy). , e Chino less Norre Honi Norre oxy, triflate Roh Leo Lome Chino less Norre e Niruokishi), - 6 alkyl which may be substituted with a group C 6 -! .
- halogen atom eg, chlorine, bromine, iodine
- an optionally halogenated ci- 6 alkylsulfonyloxy group eg, methinolesnorephoninoreoxy
- e Chino less Norre Honi Norre oxy triflate Roh Leo Lome Chino less Norre e Niruokishi
- Aryl sulfonyloxy groups eg, benzenesulfo-loxy, 41-toluenesulfonyloxy
- hydroxy groups and the like can be mentioned.
- a halogen atom, an optionally halogenated- 6 alkylsulfonyloxy group, and the like are preferable.
- This reaction can be performed in a solvent that does not adversely influence the reaction and, if necessary, in the presence of a base.
- Examples of the solvent that does not adversely influence the reaction include those exemplified in the above [Method A], water and the like. Two or more of these solvents may be mixed at an appropriate ratio.
- the amount of compound (2b-2) to be used is generally 1-10 molar equivalents, preferably 1-5 molar equivalents, per 1 mol of compound (2b-1).
- the base for example, those exemplified in the aforementioned [Method A] can be used.
- the amount of the base to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2b-l).
- the reaction temperature is usually from 10 to 100 ° C, preferably from 0 to 60 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the compound (2b-1) used as the raw material compound can be produced by [Method G] described later.
- the compound (2 b -2) used as the raw material compound can be produced by a method known per se.
- the compound (lib) in which Xa is NH can be produced, for example, by subjecting the compound (2c) to an S-methylation reaction and then subjecting it to a cyclization reaction.
- the s-methylation reaction and cyclization reaction can be carried out in a solvent that does not adversely influence the reaction, if necessary, in the presence of a base.
- the S-methylation reaction is performed according to a method known per se using a methylating reagent.
- the reagent include methyl iodide and dimethyl sulfate.
- the amount of the reagent to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2c).
- the base examples include alkali metal carbonates such as potassium carbonate and sodium carbonate; alkali metal hydroxides such as potassium hydroxide and sodium hydroxide; tertiary amines such as triethylamine; cyclic amines such as pyridine.
- the amount of the base to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2c).
- the reaction temperature for the S-methylation reaction is usually from 10 to 100 ° C, preferably from 0 to 40 ° C.
- the reaction time of the S-methylation reaction is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the cyclization reaction is performed in the presence of a base according to a method known per se.
- the cyclization reaction may proceed under the conditions of the S-methylation reaction. Alternatively, this cyclization reaction proceeds by raising the reaction temperature after the formation of the S-methyl compound.
- the base include alkali metal carbonates such as potassium carbonate and sodium carbonate; alkali metal hydroxides such as potassium hydroxide and sodium hydroxide; And tertiary amines such as min; cyclic amines such as pyridine.
- the amount of the base used is usually 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, relative to 1 mol of the S-methyl compound obtained by the S-methylation reaction.
- the reaction temperature for the cyclization reaction is usually 20 to 150, preferably 50 to 100 ° C.
- the reaction time for the cyclization reaction is usually 0.5 to 100 hours, preferably 6 to 48 hours.
- the raw material compound (2c) can be produced by [Method H] described later.
- the compound (2al) used as the raw material compound in [Method A] is produced by a method known per se. be able to.
- the compound (2 a-la) in which L is a halogen atom can be produced by the following [Method D] or [Method E].
- Compound (2 a-1 a) can be prepared, for example, by reacting compound (2 d-1) with compound (2 d-2) to produce compound (2 e), and reducing compound (2 e) To produce a compound (2 f), subject the compound (2 f) to a cyclization reaction to produce a compound (2 g), and subject the compound (2 g) to a halogenation reaction. Can be manufactured.
- Q is a leaving group
- L ′ is a halogen atom
- other symbols are as defined above.
- Examples of the leaving group represented by Q include a halogen atom (eg, fluorine, chlorine, fluorine, iodine), an optionally halogenated Ci 16 alkylsulfonyloxy group (eg, methinoresnore). Honinoleoxy, ethylsulfoninoleoxy, trifluoromethylsulfonyloxy), — C 6 _ optionally substituted with 6 alkyl groups!
- arylreshonono reoxy group eg, benzene sulphononi / reoxy, 4-toluen sulphoeroxy
- a halogen atom, an optionally halogenated Ci 16 alkylsulfonyloxy group, and the like are preferable.
- halogen atom represented by L ′ chlorine, bromine or iodine is used.
- the reaction between compound (2 d- l) and compound (2 d-2) can be carried out in a solvent that does not adversely influence the reaction, if necessary, and in the presence of a base if necessary. .
- solvents that do not adversely affect the reaction include ether solvents (eg, jetyl ether, tetrahydrofuran, dioxane), hydrocarbon solvents (eg, benzene, toluene, hexane, heptane), haguchi Examples include hydrogenated hydrocarbon solvents (eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride), nitrile solvents (eg, acetonitrile), amide solvents (eg, dimethylformamide), water, etc. It is done. Two or more of these solvents may be mixed at an appropriate ratio.
- ether solvents eg, jetyl ether, tetrahydrofuran, dioxane
- hydrocarbon solvents eg, benzene, toluene, hexane, heptane
- haguchi Examples include hydrogenated hydrocarbon solvents (eg, dichloromethane, dichloroe
- Examples of the base include amines such as triethylamine, diisopropylethylamine, 4-dimethylaminopyridine, triethylenediamine, tetramethylethylenediamine, N-methylmorpholine; potassium carbonate, sodium carbonate, etc.
- Examples include alkali metal carbonates; hydrogen carbonates such as sodium hydrogen carbonate and sodium hydrogen carbonate.
- the amount of the base to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2 d-1).
- the amount of compound (2 d— 2) used is usually 1 to 1 mol of compound (2 d— l).
- this reaction may be carried out in the presence of an alkali metal fluoride such as potassium fluoride or sodium fluoride (SYNTHE SIS, 1990, (5), p 430).
- an alkali metal fluoride such as potassium fluoride or sodium fluoride (SYNTHE SIS, 1990, (5), p 430).
- the usage-amount of an alkali metal fluoride is 1-5 molar equivalent normally with respect to 1 mol of compounds (2 d-1), Preferably it is 1-1.5 molar equivalent.
- the reaction temperature is generally 0 to 200 ° C, preferably 20 to 170 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the reduction reaction of compound (2 e) is carried out when ring A a and B a 1 do not have a functional group (for example, a halogen atom, a benzylamino group, or a benzyloxy group) that causes a more chemical reaction than a catalytic hydrogenation reaction. It is carried out by catalytic hydrogenation reaction.
- a functional group for example, a halogen atom, a benzylamino group, or a benzyloxy group
- the catalytic hydrogenation reaction can be carried out, for example, by using a catalyst (eg, platinum oxide; or palladium, ruthenium, rhodium, iridium; Raney nickel attached to activated carbon, palladium sulfate, calcium carbonate, etc.) and a hydrogen source (eg, hydrogen, cyclohexane). Hexene, hydrazine, ammonium formate).
- a catalyst eg, platinum oxide; or palladium, ruthenium, rhodium, iridium; Raney nickel attached to activated carbon, palladium sulfate, calcium carbonate, etc.
- a hydrogen source eg, hydrogen, cyclohexane. Hexene, hydrazine, ammonium formate.
- the amount of the catalyst to be used is generally 0.01 to 5 grams, preferably 0.1 to 0.5 grams, per 1 gram of compound (2e).
- This reaction can be carried out in a solvent that does not adversely influence the reaction and, if necessary, in the presence of an acid.
- Examples of the solvent that does not adversely influence the reaction include those exemplified in the above [Method B]. Two or more of these solvents may be mixed at an appropriate ratio.
- Examples of the acid include formic acid, acetic acid, hydrochloric acid, methanesulfonic acid, 4-toluenesulfonic acid and the like.
- the use pressure is usually 1 to 10 atm, preferably 1 to 2 atm.
- the reaction temperature is generally 0-100 ° C, preferably 20-60 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- ring A a and B a 1 are formed by catalytic hydrogenation reaction.
- Hydrosanolite sodium 2) Metals (eg, iron, zinc) and acidic compounds (eg,,) when they have functional groups that cause chemical reactions (eg, halogen atoms, benzylamino groups, benzyloxy groups) In combination with hydrochloric acid, sulfuric acid, methanesulfonic acid, ammonium chloride); 3) metal hydrides (eg, nickel borohydride);
- This reaction can be carried out in a solvent that does not adversely influence the reaction.
- hydrosulfite sodium or a combination of metals and acidic compounds for example, alcohol solvents (eg, methanol, ethanol, propanol), ether solvents (eg, jetyl ether) , Tetrahydrofuran, dioxane), hydrocarbon solvents (eg, benzene, toluene, hexane, heptane), halogenated hydrocarbon solvents (eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride), nitrile Solvent (eg, acetonitrile), amide solvent (eg, dimethylformamide), water, etc .;
- alcohol solvents eg, methanol, ethanol, propanol
- ether solvents eg, jetyl ether
- Tetrahydrofuran dioxane
- hydrocarbon solvents eg, benzene, toluene, hexane, heptane
- ether solvents eg, diethyl ether, tetrahydrofuran, dioxane
- hydrocarbon solvents eg, benzene, toluene, hexane, heptane
- halogenated hydrocarbon solvents eg Examples include dichloromethane, dichloroethane, chloroform, carbon tetrachloride
- nitrile solvents eg, acetonitrile
- amide solvents eg, dimethylformamide
- the amount of the reducing agent to be used is generally 1 to 100 molar equivalents, preferably 1 to 50 molar equivalents, per 1 mol of compound (2 e).
- the reaction temperature is usually from 1 to 15 ° C., preferably from 0 to 110 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the cyclization reaction of compound (2 ⁇ ) can be carried out in a solvent that does not adversely influence the reaction, using a cyclic urea synthesis reagent, if necessary, in the presence of a base.
- solvents that do not adversely affect the reaction include ether solvents (eg, jet ether, tetrahydrofuran, dioxane), hydrocarbon solvents (eg, benzene, toluene, hexane, heptane), halogenated hydrocarbon solvents.
- Cyclic urea synthesis reagents include, for example, phosgene or its related compounds (eg, triphosgene), 1,1 strength sulfonyldiimidazole, carbonate compounds (eg, diphenolate carbonate, dimethylolate carbonate, jetinole). Carbonate, 2-oxo-1,3-dioxolane), halogenated formate (eg, methyloline chloroformate, ethinore chloroformate, phenolate chloroformate, 4-12 trophyl chloroformate), etc. are used.
- phosgene or its related compounds eg, triphosgene
- 1,1 strength sulfonyldiimidazole carbonate compounds (eg, diphenolate carbonate, dimethylolate carbonate, jetinole).
- halogenated formate eg, methyloline chloroformate, ethinor
- the amount of the synthesis reagent to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2 ⁇ ).
- the base for example, those exemplified in the above [Method] can be used.
- the amount of the base to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2 f).
- the reaction temperature is usually ⁇ 10 to 100 ° C., preferably 0 to 30 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the halogenation reaction of compound (2 g) can be carried out using a halogenating reagent in a solvent that does not adversely influence the reaction, if necessary.
- halogenating reagent examples include thionyl chloride, phosphoryl chloride, phosphorus pentachloride, phosphorus tribromide and the like.
- the amount of the halogenating reagent to be used is generally 1 to 20 molar equivalents, preferably 2 to 10 molar equivalents, per 1 mol of compound (2 g).
- solvents that do not adversely affect the reaction include ether solvents (eg, jet ether, tetrahydrofuran, dioxane), hydrocarbon solvents (eg, benzene, toluene, hexane, heptane), halogenated hydrocarbons.
- Solvent eg, dichloromethane, dichloroethane, black mouth form, carbon tetrachloride
- ester solvent eg, dichloromethane, dichloroethane, black mouth form, carbon tetrachloride
- the reaction temperature is usually 0 to 120 ° (: preferably 20 to 100 ° C).
- the reaction time is usually 0.5 to: L 00 hours, preferably 1 to 48 hours.
- Compound (2 a-la) can also be produced by subjecting compound (2 f) to cyclization reaction to produce compound (2 h), and subjecting compound (2 h) to halogenation reaction. .
- the cyclization reaction of compound (2 f) can be carried out, for example, using an orthoformate ester in a solvent that does not adversely influence the reaction if necessary, and in the presence of an acid if necessary.
- orthoformate examples include methyl orthoformate and ethyl orthoformate.
- the amount of orthoformate used is usually 1 to 20 molar equivalents, preferably 1 to 10 molar equivalents, per 1 mol of compound (2 f).
- solvents that do not adversely affect the reaction include ether solvents (eg, Cyl ether, tetrahydrofuran, dioxane), hydrocarbon solvents (eg, benzene, toluene, hexane, heptane), halogenated hydrocarbon solvents (eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride), amino Solvent (eg, dimethylformamide), ester solvent (eg, methyl acetate, ethyl acetate) and the like. Two or more of these solvents may be mixed at an appropriate ratio.
- ether solvents eg, Cyl ether, tetrahydrofuran, dioxane
- hydrocarbon solvents eg, benzene, toluene, hexane, heptane
- halogenated hydrocarbon solvents eg, dichloromethane, dichloroethane, chloroform, carbon
- the acid examples include hydrochloric acid, sulfuric acid, methanesulfonic acid, Lewis acid (eg, zinc chloride, iron chloride, titanium chloride) and the like.
- the amount of the acid to be used is generally 0.05 to 5 molar equivalents, preferably 0.1 to 1 molar equivalents relative to 1 mol of compound (2 f).
- the reaction temperature is usually 0 to 100 ° C., preferably 20-60 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the halogenation reaction of compound (2 h) can be performed using a halogenating reagent in a solvent that does not adversely influence the reaction.
- halogenating reagent examples include N-prosuccinic acid imide, N-chlorosuccinic acid imide, bromine, chlorine and the like.
- the amount of the halogenating reagent to be used is generally 1 to 10 molar equivalents, preferably 1 to 3 molar equivalents, per 1 mol of the compound (2 h).
- solvents that do not adversely affect the reaction include ether solvents (eg, jet ether, tetrahydrofuran, dioxane), hydrocarbon solvents (eg, benzene, toluene, hexane, heptane), halogenated hydrocarbon solvents. (Examples: dichloromethane, dichloroethane, black mouth form, carbon tetrachloride).
- the reaction temperature is usually from 1 to 100 ° C, preferably from 0 to 60 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the compound (2 f) used as the starting compound can be produced by the above [Method D] or a method known per se.
- Compound (2a-lb) can be produced by reacting compound (2b-1) with a methylating reagent.
- Compound (2 a-1 c) can be produced by subjecting compound (2 a 1 l b) to an oxidation reaction.
- methylating reagent used for the production of the compound (2 a- l b) for example, those exemplified in the above [Method C] can be used.
- the amount of the reagent to be used is generally 1 to 10 molar equivalents, preferably 2 to 5 molar equivalents, per 1 mol of compound (2 b-1).
- This reaction can be carried out in a solvent that does not adversely influence the reaction.
- ether solvents eg, jet ether, tetrahydrofuran, dioxane
- hydrocarbon solvents eg, benzene, toluene, hexane, heptane
- halogenated hydrocarbons e.
- Solvents eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride), ketone solvents (eg, acetone, 2-butanone), nitrile solvents (eg, acetonitrile), amide solvents (eg, dimethylformamide) ), Ester solvents (eg, methyl acetate, ethyl acetate), water and the like.
- the reaction temperature is usually 10 to 100 ° C, preferably 0 to 30 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the oxidation reaction of compound (2 a- l b) is carried out using an oxidizing agent in a solvent that does not adversely influence the reaction.
- solvents that do not adversely affect the reaction include hydrocarbon solvents (eg, ben Zen, toluene, hexane, heptane), halogenated hydrocarbon solvents (eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride), amide solvents (eg, dimethylformamide), ester solvents (eg Examples include methyl acetate, ethyl acetate), acetic acid, water and the like.
- hydrocarbon solvents eg, ben Zen, toluene, hexane, heptane
- halogenated hydrocarbon solvents eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride
- amide solvents eg, dimethylformamide
- ester solvents eg Examples include methyl acetate, ethyl acetate), acetic acid, water and the like.
- oxidizing agent examples include m-chloroperbenzoic acid, oxone, hydrogen peroxide solution, and the like.
- the amount of the oxidizing agent to be used is generally 2 to 5 molar equivalents, preferably 2 to 4 molar equivalents, per 1 mol of compound (2a-lb).
- the reaction temperature is usually from 10 to 100 ° C, preferably from 0 to 40 ° C.
- the reaction time is usually 0.5 to: I 00 hours, preferably 1 to 48 hours.
- the compound (2 b-1) used as the starting compound in the above [Method B] and [Method F] can be produced, for example, by the following [Method G].
- Compound (2 b-1) can be produced, for example, by reacting compound (2 f) with a thiocarbonylating reagent.
- This reaction can be performed in a solvent that does not adversely influence the reaction and, if necessary, in the presence of a base.
- Examples of the solvent that does not adversely influence the reaction include those exemplified in the cyclization reaction of the compound (2 f) in the above [Method D]. Two or more of these solvents may be mixed at an appropriate ratio.
- thiocarbonylation reagent examples include thiophosgene, 1,1, -thiocarbonyldiimidazole, carbon disulfide, and the like.
- the amount of the reagent to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2 f).
- Examples of the base include amines such as triethylamine and pyridine.
- the amount of the base to be used is generally 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2 f). .
- the reaction temperature is usually from 1 to 100 ° C, preferably from 0 to 50 ° C.
- the reaction time is usually 0.5 to: L 00 hours, preferably 1 to 48 hours.
- the compound (2c) used as the raw material compound can be produced, for example, by the following [Method H].
- Compound (2 c) can be produced, for example, by reacting compound (2 f) with compound (2 i).
- This reaction can be performed in a solvent that does not adversely influence the reaction and, if necessary, in the presence of a base.
- Examples of the solvent that does not adversely influence the reaction include those exemplified in the cyclization reaction of the compound (2 f) in the above [Method D]. Two or more of these solvents may be mixed at an appropriate ratio.
- the amount of compound (2 i) to be used is generally 1 to 5 mol equivalent, preferably 1 to 3 mol equivalent, per 1 mol of compound (2 f).
- the base for example, those exemplified in the aforementioned [Method G] can be used.
- the amount of the base to be used is generally 0.5 to 10 molar equivalents, preferably 1 to 5 molar equivalents, per 1 mol of compound (2 i).
- the reaction temperature is usually 1 to 10 ° C, preferably 0 to 40 ° C.
- the reaction time is usually 0.5 to 100 hours, preferably 1 to 48 hours.
- the compound (2 i) used as the raw material compound can be produced by a method known per se.
- Functional groups to which the rings A a, B a 1 and B a 2 of the compound (II) can be converted for example, a carboxyl group, an amino group, a hydroxy group, a carbonyl group, a mercapto group, an ester group, a sulfo group, a halogen atom)
- a variety of compounds can be produced by converting the functional group by a method known per se or a method analogous thereto.
- the carboxyl group can be converted by, for example, a reaction such as esterification, reduction, amidation, or a conversion reaction to an optionally protected amino group.
- the amino group can be converted by, for example, reactions such as amidation, sulfonylation, nitrosation, alkylation, arylation, imidization.
- the hydroxy group can be converted by, for example, reactions such as esterification, strong rumoylation, sulfonylation, alkylation, arylation, oxidation, and halogenation.
- the carbonyl group can be converted by reactions such as reduction, oxidation, imination (including oximation and hydrazone formation), (thio) ketalization, alkylidene formation, and thiocarbonylation.
- Mercapto groups can be converted, for example, by reactions such as alkylation and oxidation.
- the ester group can be converted by a reaction such as reduction or hydrolysis.
- the sulfo group can be converted by a reaction such as sulfonamidation or reduction.
- the halogen atom can be converted by, for example, various nucleophilic substitution reactions, various coupling reactions, and the like.
- the compound when the compound is obtained in a free state, it may be converted into a salt according to a conventional method, and when it is obtained as a salt, it is converted into a free form or other salt according to a conventional method. You can also.
- the starting compound is substituted with an amino group
- a protective group generally used in peptide chemistry or the like may be introduced into these groups.
- the target compound can be obtained by removing.
- the protecting group of Amino groups such as formyl group; a substituents may be respectively, C j _ 6 alkyl one carbonyl group, Hue - Rukarubo group, - 6 alkoxy one carbonyl group, Ariruo Xoxycarbonyl (A 1 1 oc) group, phenyloxycarbonyl group, fluorenylmethyloxycarbonyl (F moc) group, C 7 —.
- Ararukiru one carbonyl group e.g., benzyl Cal Poni Le
- C 7 - 0 Ararukiru one Okishikarubo - Le group e.g., benzyl O carboxymethyl Cal Poni Le (Z)
- C 7 - 2 0 Ararukiru group e.g., benzyl, trityl
- substituents phenyl group, a halogen atom, - 6 alkyl Ichiriki Ruponiru group, Bruno, optionally halogenated C - 6 alkoxy group, nitro group and the like, the number of substituents is from 1 About three.
- each of them may have a substituent.
- _ 6 alkyl group Ariru group, C 7 _ 2.
- Aralkyl groups eg, benzyl, trityl
- phenyl groups eg, trialkylsilyl groups (eg, trimethylsilyl, tert-butyldimethylsilyl, diisopropylethylsilyl) and the like.
- substituents a halogen atom, a formyl group, a 6- alkyl monocarbonyl group, an optionally halogenated 6- alkoxy group, a nitro group, etc. are used, and the number of substituents is 1 to 3 Degree.
- the substituents may be respectively, C X _ 6 alkyl groups, C 7 - 2.
- Aralkyl group eg, benzyl, trityl
- Honolemil group — 6 Alkyl group, Lonyl group, Benzyl group, C 7 — i Q
- Aralkyl group Lonyl group (eg, Benzylcarbonyl), Tetrahydropyrael group, Furanyl group And trialkylsilyl group (eg, trimethylsilyl, tert-butyldimethylsilyl, diisopropylethylsilyl) and the like.
- the protection group of mercapto includes, for example, the substituents may be respectively, C a _ 6 alkyl groups, C i -. 6 alkyl one carbonyl group, C 7 - 2.
- Aralkyl groups eg, benzyl, trityl
- substituents include halogen atoms, — 6 alkyl groups, phenyl groups, C 7 — 6 aralkyl groups, —
- the number of substituents is about four from 1.
- a method for removing the protecting group a method known per se or a method equivalent thereto is used. For example, acid, base, reduction, ultraviolet light, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetraptyl A method of treating with ammonium fluoride, palladium acetate or the like is used.
- reaction mixture obtained by methods known per se, such as extraction, concentration, neutralization, filtration, distillation, recrystallization, column Isolation and purification by means such as chromatography, thin layer chromatography, preparative high performance liquid chromatography (preparative HPLC), medium pressure preparative liquid chromatography (medium pressure preparative LC) Can do.
- compound (I) may have optical isomers, any of these individual optical isomers and mixtures thereof are naturally included in the scope of the present invention. If desired, these isomers are known per se. It can be optically divided according to the means or manufactured separately.
- Compound (I) 1 When present as a configurational isomer (configuration isomer), diastereomer, conformer, etc., each can be isolated by the above-described separation and purification means, if desired. Further, when the compound (I) is a racemate, it can be separated into an S form and an R form by an ordinary optical resolution means.
- Compound (I) may be hydrated or non-hydrated.
- Compound (I) may be labeled with an isotope (eg, 3 H, 14 C, 35 S).
- Compound (I), Compound (II) and their prodrugs (hereinafter sometimes abbreviated as compounds of the present invention) have GPR40 receptor function-modulating action, particularly GPR40 receptor antagonist activity.
- GPR40 receptor function-modulating action particularly GPR40 receptor antagonist activity.
- low toxicity eg acute toxicity, chronic toxicity, genetic toxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicity
- it is a safe GPR 40 receptor modulator, preferably GPR 40 Useful as an antagonist.
- the compound of the present invention is useful as a modulator of physiological functions involving GPR40 receptor or as a prophylactic / therapeutic agent for pathological conditions or diseases involving GPR40 receptor.
- the compound of the present invention is useful as an insulin secretion regulator (preferably an insulin secretion inhibitor), an obesity-improving agent, a knee-protecting agent (knee) 3-cell protecting agent), and an insulin resistance-improving agent. is there.
- fatty acid promotes insulin secretion from knee / 3 cells, but excessive insulin secretion is thought to promote obesity and enhance insulin resistance.
- excessive fatty acid stimulation of insulin secretion in knee 3 cells is thought to cause knee fatigue. Therefore, a drug that suppresses excessive insulin secretion from knee / 3 cells is useful as an agent for preventing / treating or improving obesity, insulin resistance, fatigue, etc.
- the agent of the present invention retains or restores the sugar-dependent insulin secretion ability, which is an important function of knee ⁇ 3 cells, by suppressing knee fatigue.
- the compounds of the present invention include, for example, diabetes (eg, type 1 diabetes, type 2 diabetes, gestational diabetes, unstable diabetes, obese diabetes), impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy Retinopathy (eg, diabetic retinopathy), obesity, meta Boric syndrome, insulin resistance, hyperinsulinemia, hypertension, hyperlipidemia (eg, hypertriglyceridemia, hypercholesterolemia, hypoHDLemia, postprandial hyperlipidemia), arteriosclerosis, Heart failure, myocardial infarction, sexual dysfunction, skin disease, arthropathy, osteopenia, thrombotic disease (eg, foot ulcer)., Memory learning disorder, depression, manic depression, schizophrenia, attention deficit hyperactivity disorder, Visual impairment, appetite regulation disorder (eg, bulimia), hypoglycemia, edema, fat atrophy, lipotoxicity, fatigue exhaustion, cancer (eg, insulinoma, breast cancer), immune system disease (eg, immunodeficiency),
- the compounds of the present invention are diabetic, diabetic neuropathy, diabetic nephropathy, retinopathy (eg, diabetic retinopathy), obesity, metapolytic syndrome, insulin resistance, Impaired glucose tolerance, hyperinsulinemia, hypertension, hyperlipidemia, arteriosclerosis, heart failure, myocardial infarction, thrombotic disease (eg, foot ulcer), memory learning disorder, manic depression, visual impairment, appetite regulation disorder, It is useful as a prophylactic / therapeutic agent for lipotoxicity, knee fatigue, immune system diseases (eg, immunodeficiency), inflammatory diseases (eg, enteritis, arthritis, allergies) or cancer (eg, breast cancer).
- immune system diseases eg, immunodeficiency
- inflammatory diseases eg, enteritis, arthritis, allergies
- cancer eg, breast cancer
- diabetes is a fasting blood glucose level (glucose concentration in venous plasma) of 126 mg / d 1 or more, 75 g transglucose tolerance test (75 gOGT T), 2 hour value (glucose concentration in venous plasma) Is at least 200 mgZd l and the blood glucose level (glucose concentration in venous plasma) is at least ZO OmgZd 1 or higher.
- “Fasting blood glucose level (glucose concentration in vein plasma) is less than 11 OmgZd 1 or 75 g oral glucose tolerance test (75 gOGTT) 2 hour value (venous plasma A state where the glucose concentration in (is not less than 14 OmgZd 1) (normal type) is called “boundary type”.
- diabetes is a fasting blood glucose level (darcose concentration in venous plasma) of 1 26 mg / d 1 or more, 75 g trans glucose tolerance test 2 hour value (glucose concentration in venous plasma) ) Is 200 mg / d 1 or higher, and anytime blood glucose level (glucose concentration in venous plasma) is 20 OmgZd 1 or higher.
- impaired glucose tolerance means that fasting blood glucose level (glucose concentration in venous plasma) is less than 12 SmgZd 1, and 75 g trans glucose load test 2 hour value (venous plasma Is a state in which the glucose concentration is 14 OmgZd 1 or more and less than 20 OmgZd 1.
- the ADA reports that the fasting blood glucose level (glucose concentration in venous plasma) is greater than or equal to l l OmgZd l 1 26 mg / d 1 and full is called I FG (Imp a i r e d F a s t i n g G l u c o s e).
- the 75 g oral pudou glucose tolerance test 2 hour value (glucose concentration in venous plasma) is less than 14 OmgZd 1 IFG (Imp aired F sting G lyc em ia no.
- the compounds of the present invention are diabetic, borderline, impaired glucose tolerance, IFG (Imp aired F asting G lucose) and I FG (Imp aired F asting G lyc em ia) determined by the above new criteria. It is also used as a preventive / therapeutic agent.
- the compounds of the present invention can be used to develop borderline, impaired glucose tolerance, IFG (Impaired Fasting Glucose) or IFG (I maired Fasting Glycemia) power to diabetes; and from obesity It can also prevent progression to diabetes.
- the compound of the present invention Since the compound of the present invention has an excellent GPR40 receptor antagonist activity, it exhibits remarkable effects (eg, therapeutic effects such as obesity and diabetes) in patients with high blood free fatty acid levels.
- the compounds of the present invention are commonly used as a method for producing pharmaceutical formulations, if desired.
- a mammal eg, mouse, rat, hamster, usagi, cat, innu, ushi, hidge, monkey, Can be safely administered orally or parenterally (eg, topical, rectal, intravenous).
- dosage forms include tablets (including sublingual tablets and intraoral disintegrating tablets), capsules (including soft capsules and microcapsules), granules, powders, lozenges, syrups, emulsions, suspensions.
- Oral preparations such as; and injections (eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, infusions), external preparations (eg, transdermal preparations, ointments), suppositories ( Examples: rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations (inhalants), and parenteral preparations such as eye drops.
- injections eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, infusions
- external preparations eg, transdermal preparations, ointments
- suppositories examples: rectal suppositories, vaginal suppositories
- pellets e.g., nasal preparations, pulmonary preparations (inhalants), and parenteral preparations such as eye drops.
- compositions may be controlled-release preparations such as immediate-release preparations or sustained-release preparations (eg, sustained-release microcapsules).
- the content of the compound of the present invention in a pharmaceutical preparation is about 0.01 to about 100% by weight of the whole preparation.
- the dose of the compound of the present invention varies depending on the administration subject, administration route, disease, symptom, etc. For example, when administered orally to an adult diabetic patient (body weight of about 6 O kg), about 0.01 To about 3 Omg / kg body weight, preferably about 0.1 to about 2 Omg / kg body weight, more preferably about 1 to about 2 Omg Z kg body weight. This amount should be divided into one to several doses per day.
- Examples of the pharmacologically acceptable carrier described above include various organic or inorganic carrier substances commonly used as pharmaceutical materials.
- excipients for example, excipients, lubricants, binders and disintegrants in solid preparations, or liquid preparations Solvents, solubilizers, suspending agents, tonicity agents, buffers and soothing agents.
- additives such as preservatives, antioxidants, colorants, sweeteners, adsorbents, wetting agents and the like can be used as necessary.
- Examples of the excipient include lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, and light anhydrous key acid.
- the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- binder examples include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropinoresenorellose, hydroxypropinoremethenoresenellose polypyrrolidone, starch, sucrose, gelatin, methylcellulose, cal Examples thereof include boxymethylcellulose sodium.
- disintegrating agent examples include starch, carboxymethylcellulose, carboxymethylcellulose calcium, force / repoxymethyl starch sodium, L-hydroxypropylcellulose, and the like.
- solvent examples include water for injection, alcohol, propylene glycol, macaque gall, sesame oil, corn oil, olive oil and the like.
- solubilizer examples include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; And hydrophilic polymers such as polybutylpyrrolidone, carboxymethylcellulose sodium, methinoresenorelose, hydroxymethinoresenorelose, hydroxychettinocellulose, and hydroxypropylcellulose.
- isotonic agent examples include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.
- buffers such as phosphates, acetates, carbonates, citrates, and the like.
- Examples of soothing agents include benzyl alcohol.
- preservatives include parahydroxybenzoates, chlorobutano —, Benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid, ⁇ -tocopherol and the like.
- colorants include water-soluble edible tar pigments (eg, edible pigments such as edible red No. 2 Oppi 3, edible yellow No. 4 and 5, edible blue No. 1 and 2), water-insoluble lakes, etc.
- examples include pigments (eg, aluminum salts of the aforementioned water-soluble edible tar pigments), natural pigments (eg, J3-carotene, chlorophyll, bengara) and the like.
- sweetening agent examples include saccharin sodium, bismuth glycyrrhizinate, aspartame, stevia and the like.
- the compound of the present invention comprises a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, a therapeutic agent for hyperlipidemia, an antihypertensive agent, an antiobesity agent, a diuretic agent, a chemotherapeutic agent, an immunotherapeutic agent, an anti-inflammatory agent, an antithrombotic agent, It can be used in combination with drugs such as osteoporosis treatment, vitamins, anti-dementia, frequent urinary / urinary incontinence, dysuria, etc. (hereinafter sometimes abbreviated as drug X).
- drugs such as osteoporosis treatment, vitamins, anti-dementia, frequent urinary / urinary incontinence, dysuria, etc. (hereinafter sometimes abbreviated as drug X).
- the above-mentioned anti-diabetic agents include insulin preparations (eg, animal insulin preparations extracted from Kushi and Puta knees; Escherichia coli and yeast genetically synthesized human insulin preparations; insulin zinc; protamine insulins) Zinc; Insulin fragment or derivative (eg INS-1), oral insulin preparation), insulin sensitivity enhancer (eg pioglitazone or its salt (preferably hydrochloride), rosiglitazone or its salt (preferably maleic acid) Salt), regrixan (R eg 1 ixane) (J TT—501), netoglitazone (Ne toglitazone) (MCC—555), F K-614, riboglitazone (R ivog 1 itazone) (CS—O il), muraglitaza Compound (Mu rag 1 itazar) (BMS-298585), WO 99/58510 (for example,
- (E) -4 [4 1 (5-Methyl-2-phenyl 4 oxazolylmethoxy) benzyloxymino] —4 1-phenylbutyric acid), WO 01Z38325 Compounds, Tesaaglitazar (AZ—242), Daglitazone (BM-1 3—1 258), LM—4 1 56, Metaglidacene (M'e taglidasen) (MBX—102), LY — 5 1 98 1 8, MX-6054, LY— 5 10 92 9, Balaglitazone (NN— 2344), T 1 1 3 1 or its salt THR- 092 1), one darcosidase inhibitor ( Examples: voglibose, carbose, miglitol, emidatetate), biguanides (eg, phenformin metformin, buformin or their salts (eg, hydrochloride, fumarate, succinate)), insulin secretion promotion Agents [sulf
- GLP-1 receptor agonist GLP-1 receptor agonist
- GLP-1 GLP-1 MR agent, NN-22 1 1, AC- 29 93 (exendi n-4 ), BIM— 5 1077, A ib (8, 35) h GLP— 1 (7, 37) NH 2 , CJC 1 1 3 3]
- Dipeptidyl peptidase IV inhibitor eg NVP— DP P— 278, PT—100, P 32/98, P 93/01, NVP—DPP—728, Vildagliptin (Vi 1 dag 1 iptin) (L AF 23 7), TS—02 1, Sitagribtin phosphate (S itagliptinphosphate) (MK—043 1), Saxagliptin (BMS-477 1 1
- adiponectin or its agonist eg AS, 286 8
- I KK inhibitor eg AS, 286 8
- levtin resistance ameliorating agent eg WO 0 1/2
- somatostatin receptor agonist eg WO 0 1/2
- aldose reductase inhibitors eg, torrestat, enorrestat, zenarestat, zoponolestat, fidarestat, lanirestat (AS-320 1), minarerestat, CT 1 1 1 2)
- Neurotrophic factor and its increasing drug eg, NGF, NT-3, BDNF, WO0 1/143 72 described in -Eurotrophin production / secretion promoter (eg 4 (4) Ninore) 1 2-— (2-Methinore 1-Imidazolinole) 1 5-— [3-— (2-Methylphenoxy) propyl] oxazole, etc.
- P KC protein kinase C
- ruboxistaurin me sylate LY—33 35 3 1
- AG ⁇ inhibitors eg, AL ⁇ —945, pimagedin, N-phenacyl thiazolium bromide (ALT—76)
- active oxygen scavengers eg, thioc acid
- cerebral vasodilators eg, thioprido
- somatostatin receptor Agonists eg, BI M231 90
- ASK-1 apoptotic signaling regulatory kinase 1
- Antihyperlipidemic agents include HMG—CoA reductase inhibitors (eg, pravastatin, simvastatin, lovastatin, atonolevastatin, fuslepastatin, pitapastatin, rospastatin or their salts (eg, sodium salt) , Calcium salts)), squalene synthase inhibitors (eg, compounds described in WO 9 7 1 0224, for example, N — [[(3R, 5S) —1— (3-acetoxy 2,2-dimethyl compound) Pills) 1-7-black mouth 5- (2,3-dimethoxyphenyl) 1 2-oxo 1 2, 3, 5—Tetrahydro-1, 4, Benzoxazepine, 3-Inole] Acetyl] Piperidine, 4-Monoacetic acid), fibrate compounds (eg, bezafibrate, clofibrate, simfibrate, clinofibrate) , Antioxidants (eg
- Antihypertensive agents include angiotensin converting enzyme inhibitors (eg, captopril, enalapril, delapril), angiotensin II antagonists (eg: oral sultan, can desanoretane cilexetinole, eprosa / letane, apeloresanoletane, tenolemisanoretane, Ilbesartan, olmesartan medoxominore, tasosartan, 1 1 [[2 '— (2, 5 — dihydro 1 5 — oxo 1 4 H— 1, 2, 4 1 oxadiazo 1 ro 3 inore) bihue-nore 1 — isle] Methinore] 1-Ethoxy 1 H-Venemidazole 7-Strength rubonic acid), calcium antagonists (eg, manidipine, diphedipine amlodipine, efonidipine, dicardi
- Anti-obesity agents include, for example, central anti-obesity drugs (eg, dexfuyunfluramine, fenfunoreramine, fuentenoremin, sibutramine, amphepramon, dexamphetamine, mazindonore, fenenorepropanolamine, clobe Nzolex; MCH receptor antagonist (eg: SB—568849; SNAP-7941; compounds described in WO 01/82925 and WO 01/8 78 34); Neuropeptide Y antagonist (eg, CP—42293 5 ); Cannabinoid receptor antagonists (eg SR— 14 1 7 1 6; SR— 147778); Grelin antagonists; 1 1 — Hydroxysystemoid dodehydrogenase inhibitors (eg 8 yen to 3498)), Knee lippers Inhibitor (eg, orlistat, ATL—962), 3agonist (eg, CL 1 3 1 6243, SR—586
- Diuretics include, for example, xanthine derivatives (eg, sodium salicylate theopromine, calcium salicylate theopromine), thiazide preparations (eg, ethiazide, cyclopenthiazide, trichloromethiazide, hydrochlorothiaziazide, hydrofnoremethiazide) , Benzinorech drarorothiazide, penfnoretizide, polythiazide, methiclotiazide), anti-aldosterone preparations (eg: spironolatathone, triamterene), carbonic anhydrase inhibitors (eg: acetazolamide), chlorbenzene sulfonamido preparations Don, mefluside, indamide), azosemide, isosorbide, ethacrynic acid, piretanide, bumetanide, furosemide and the like.
- chemotherapeutic agents include alkylating agents (eg, cyclophosphamide, ifosfamide), antimetabolites (eg, methotrexate, 5-fluorouracil and its derivatives), anticancer antibiotics (eg, my Tomycin, adriamycin), plant-derived anticancer agents (eg, vincristine, vindesine, taxol), cis-bratin, carpoplatin, etoposide and the like.
- alkylating agents eg, cyclophosphamide, ifosfamide
- antimetabolites eg, methotrexate, 5-fluorouracil and its derivatives
- anticancer antibiotics eg, my Tomycin, adriamycin
- plant-derived anticancer agents eg, vincristine, vindesine, taxol
- cis-bratin carpoplatin, etoposide and the like.
- immunotherapeutic agents include microorganisms or bacterial components (eg, muramyl dipeptide derivatives, picipanil), polysaccharides with immunopotentiating activity (eg, lentinan, schizophyllan, krestin), and genetic engineering techniques.
- Site force in eg, interferon, interleukin (IL)
- colony stimulating factor eg, granulocyte colony stimulating factor, erythropoietin
- anti-inflammatory drug examples include non-steroidal anti-inflammatory drugs such as aspirin, acetaminophen, and indomethacin.
- Antithrombotic agents include, for example, heparin (eg, heparin sodium, heparinka noresum, danoreteno ⁇ ) phosphine sodium (dalteparinsodi um), anti-thrombin (eg: sulfaline calium), antithrombin drug (eg: argatro Non-argatroban), thrombolytic keratin (eg, urokinase), Tisokina 'I (tisokina S e), alteplase (a 1 te 1 ase), nateprase, ⁇ nate 1 ase, monte braze (mo nte 1 ase), nomitelase (amite 1 ase)), platelet aggregation inhibitor (eg, tic 1 o Pidinehydroch 1 oride), cilostazo 1, icosapentate ethenole, beraprost sodium (Beraprostsodium) and s
- osteoporosis treatment agents examples include alpha force noreside-nore (a 1sammlung 1 cidol), canole citrionore (ca 1 citrio 1), el force tonin (e 1 catonin), salmon calcitonin (ca 1 citoninsa 1 mon) estriol (estrio 1), ypriflavone (iprif 1 avone), risedronated isodium, risedronatedisodium, p am idronatedisodium, alendronate sodium hydrate (a 1 endronatesodiumhydrat e), Incadronated isodi urn and the like.
- vitamin drugs examples include vitamin B and vitamin 2 .
- anti-dementia agent examples include tacrine, donepezi 1, rivasti gm ine, galantham ine and the like.
- Examples of frequent urinary and urinary incontinence drugs include flavoxate hydrochloride (f 1 a V o X at e h y d r o c h l o r i d e), oxypeptinine hydrochloride (o x y b u t y n i n h d d e) 7 roherin hydrochloride r o p e v e r e n e h r
- dysuria treatment agents examples include acetylcholinesterase inhibitors (eg distig) Min) and the like.
- drugs that have been shown to improve cachexia in animal models and clinically drugs that have been shown to improve cachexia in animal models and clinically: cycloxygen " ⁇ -one inhibitor (eg, indomethacin), progesterone derivatives (eg, megesterol acetate)", sugar Steroids (eg, dexamethasone), methocralamide, tetrahydrocannabinol, fat metabolism improver (eg, eicosapentaenoic acid), growth hormone, IGF-1 or factors that induce cachexia Antibodies against TNF-a, LIF, IL-6, Oncostatin M, etc. can also be used in combination with the compound of the present invention.
- ⁇ -one inhibitor eg, indomethacin
- progesterone derivatives eg, megesterol acetate
- sugar Steroids eg, dexamethasone
- methocralamide etrahydrocannabinol
- fat metabolism improver eg, eico
- glycation inhibitors eg ALT-7 1 1
- nerve regeneration promoters eg Y—128, VX853, prosaptide
- antidepressants eg desipramine, amitriptyline, imibramin
- antiepileptics Drugs eg Lamotrigine, Trileptanol (Tri 1 epta 1), Kepla (K eppra), Zonegran (Z onegran), Pregianoline (P regabalin), Nococoselide (H arkoseride), Carbamazepine (Antiarrhythmic)
- mexiletine mexiletine
- acetylcholine receptor ligands example: ABT-594
- endothelin receptor antagonists example: ABT-627
- monoamine uptake inhibitors example: tramadol
- narcotic analgesics example: Morphine
- GABA receptor agonist eg, gearbapentin, gabapentin
- Two or more kinds of the above-mentioned drugs X may be used in combination at an appropriate ratio.
- the administration timing of the compound of the present invention and drug X is not limited, and the compound of the present invention and drug X may be administered simultaneously to the administration subject. It may be administered with a time difference.
- the dose of drug X may be in accordance with the clinically used dose, and can be appropriately selected depending on the administration subject, administration route, disease, combination and the like.
- the administration mode of the compound of the present invention and the drug X is not particularly limited as long as the compound of the present invention and the drug X are combined at the time of administration.
- dosage forms include: (1) administration of a single preparation obtained by simultaneously formulating the compound of the present invention and drug X; and (2) separate administration of the compound of the present invention and drug X.
- the time difference in the same route of administration of the two formulations obtained by separately formulating the compound of the present invention and Drug X Simultaneous administration of two kinds of preparations obtained by separately formulating the compound of the present invention and Drug X through different administration routes, (5) Separately administering the compound of the present invention and Drug X Administration of the two types of preparations obtained by formulating in different time intervals by different administration routes (for example, the compound of the present invention; administration in the order of drug X, or administration in the reverse order), etc. It is possible.
- the present invention further relates to “a GPR 40 receptor antagonistic method characterized by administering an effective amount of a non-peptide nitrogen-containing heterocyclic compound to a mammal”.
- mammals include mouse, rat, hamster, usagi, cat, inu, ushi, hidge, monkey and human.
- the non-peptidic nitrogen-containing heterocyclic compound may be any non-peptidic compound having a nitrogen-containing heterocyclic ring (preferably a nitrogen-containing fused heterocyclic ring) as a partial structure. And the like.
- Examples of the effective amount of the non-peptide nitrogen-containing heterocyclic compound include the dose of the compound of the present invention described above.
- This antagonistic method can be used to regulate physiological functions involving GPR 40 receptors or GPR 40 Useful for the prevention and treatment of conditions or diseases involving receptors.
- This antagonistic method is particularly useful in mammals for diabetes, diabetic neuropathy, diabetic nephropathy, retinopathy (eg, diabetic retinopathy), obesity, meta-polyc syndrome, insulin resistance, impaired glucose tolerance.
- Hyperinsulinemia hypertension, hyperlipidemia, arteriosclerosis, heart failure, myocardial infarction, thrombotic disease (eg, foot ulcer), memory learning disorder, manic depression, visual impairment, appetite regulation disorder, lipotoxicity, ⁇ It is used to treat exhaustion, immune system diseases (eg, immunodeficiency), inflammatory diseases (eg, enteritis, arthritis, allergies) or cancer (eg, breast cancer).
- immune system diseases eg, immunodeficiency
- inflammatory diseases eg, enteritis, arthritis, allergies
- cancer eg, breast cancer
- Root temperature in the following Reference Examples and Examples usually indicates about 10 ° C. to about 35 ° C. % Indicates the yield of m o 1 / m o 1%, the solvent used in the chromatography is volume%, and the others are weight%.
- MS measuring instrument Waters ZMD, Waters ZQ2000 or Micros platform II ionization method: Electron Spray Ionization (ESI) or Atmospheric Pressure Chemical Ionization (APCI). ESI was used unless otherwise specified.
- Solvent Liquid A; 0.1% Trifluoroacetic acid-containing water,
- Liquid B 0.1% Triacetoacetonitrile containing acetonitrile
- the title compound was purchased from Enamine.
- the title compound was purchased from Enamine.
- the title compound was purchased from Ivonin.
- the title compound was purchased from Ivonin.
- the title compound was purchased from Enaraine.
- the title compound was purchased from Ivonin.
- the title compound was purchased from Enamine.
- the title compound was purchased from Ivonin.
- the title compound was purchased from Enamine.
- the title compound was purchased from Ivonin.
- the title compound was purchased from Ivonin.
- the title compound was purchased from SPECS & BIOSPECS.
- the title compound was purchased from IF LTD.
- the title compound was purchased from Enaraine.
- the title compound was purchased from Enamine.
- the title compound was purchased from Enamine.
- the title compound was purchased from Ivonin.
- the title compound was purchased from Ivonin.
- the title compound was purchased from Volovenko.
- the title compound was purchased from Volovenko.
- the title compound was purchased from INTELBI0SCAN.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Vascular Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002583326A CA2583326A1 (en) | 2004-10-08 | 2005-10-07 | Receptor function regulating agent |
EP05793826A EP1810677A1 (en) | 2004-10-08 | 2005-10-07 | Receptor function regulating agent |
JP2006539360A JPWO2006038738A1 (ja) | 2004-10-08 | 2005-10-07 | 受容体機能調節剤 |
US11/664,728 US20080021069A1 (en) | 2004-10-08 | 2005-10-07 | Receptor Function Regulating Agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-296963 | 2004-10-08 | ||
JP2004296963 | 2004-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006038738A1 true WO2006038738A1 (ja) | 2006-04-13 |
Family
ID=36142792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/018908 WO2006038738A1 (ja) | 2004-10-08 | 2005-10-07 | 受容体機能調節剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080021069A1 (ja) |
EP (1) | EP1810677A1 (ja) |
JP (1) | JPWO2006038738A1 (ja) |
CA (1) | CA2583326A1 (ja) |
WO (1) | WO2006038738A1 (ja) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009049492A1 (fr) * | 2007-10-12 | 2009-04-23 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Composés de diaryléthers multi-substitués et d'aniline d'hydrocarbures aromatiques n-substitués |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015095256A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
WO2015097713A1 (en) | 2013-11-14 | 2015-07-02 | Cadila Healthcare Limited | Novel heterocyclic compounds |
WO2015176640A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
WO2016019863A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
US10519115B2 (en) | 2013-11-15 | 2019-12-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
US7750048B2 (en) * | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
JP2012503595A (ja) | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
EP2538784B1 (en) * | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
US9499467B2 (en) | 2011-04-08 | 2016-11-22 | Caldan Therapeutics Limited | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
JP6273129B2 (ja) * | 2013-11-20 | 2018-01-31 | 株式会社エンプラス | 密閉容器および密閉容器セット |
WO2015081463A1 (en) * | 2013-12-02 | 2015-06-11 | Novartis Ag | Egfr inhibitor forms |
US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
AP2016009371A0 (en) | 2014-02-11 | 2016-08-31 | Bayer Pharma AG | Benzimidazol-2-amines as midh1 inhibitors |
CN104262330B (zh) * | 2014-08-27 | 2016-09-14 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
CA2965213A1 (en) | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors |
EP3209646B1 (en) | 2014-10-23 | 2020-07-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Benzimidazol-2-amines as midh1 inhibitors |
US10370339B2 (en) | 2015-06-08 | 2019-08-06 | Bayer Pharma Aktiengesellschaft | N-Methylbenzimidazoles as mIDH1 inhibitors |
JP6824954B2 (ja) | 2015-07-16 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | mIDH1阻害剤としての5−ヒドロキシアルキルベンズイミダゾール |
GB201700587D0 (en) | 2017-01-13 | 2017-03-01 | Redag Crop Prot Ltd | Agricultural chemicals |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002522431A (ja) * | 1998-08-06 | 2002-07-23 | ファイザー製薬株式会社 | Orl1レセプターアゴニストとしての2−置換−1−ピペリジルベンゾイミダゾール化合物 |
WO2002088107A1 (en) * | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
WO2003006438A1 (de) * | 2001-07-09 | 2003-01-23 | Schering Aktiengesellschaft | Benzimidazolderivate zur behandlung von mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen |
WO2003088967A1 (en) * | 2002-04-18 | 2003-10-30 | Schering Corporation | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
WO2004014369A1 (en) * | 2002-08-07 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI91754C (fi) * | 1986-12-02 | 1994-08-10 | Tanabe Seiyaku Co | Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi |
AU770600B2 (en) * | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
US6903126B2 (en) * | 2001-07-09 | 2005-06-07 | Schering Ag | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
-
2005
- 2005-10-07 WO PCT/JP2005/018908 patent/WO2006038738A1/ja active Application Filing
- 2005-10-07 CA CA002583326A patent/CA2583326A1/en not_active Abandoned
- 2005-10-07 EP EP05793826A patent/EP1810677A1/en not_active Withdrawn
- 2005-10-07 US US11/664,728 patent/US20080021069A1/en not_active Abandoned
- 2005-10-07 JP JP2006539360A patent/JPWO2006038738A1/ja not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002522431A (ja) * | 1998-08-06 | 2002-07-23 | ファイザー製薬株式会社 | Orl1レセプターアゴニストとしての2−置換−1−ピペリジルベンゾイミダゾール化合物 |
WO2002088107A1 (en) * | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
WO2003006438A1 (de) * | 2001-07-09 | 2003-01-23 | Schering Aktiengesellschaft | Benzimidazolderivate zur behandlung von mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen |
WO2003088967A1 (en) * | 2002-04-18 | 2003-10-30 | Schering Corporation | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
WO2004014369A1 (en) * | 2002-08-07 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
Non-Patent Citations (1)
Title |
---|
SHINOZAKI K ET AL: "Stress and vascular responses: oxidative stress and endothelial dysfunction in the insulin-resistant state.", J PHARMACOL SCI., vol. 91, no. 3, 2003, pages 187 - 191, XP002993686 * |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8148396B2 (en) | 2005-06-09 | 2012-04-03 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8158648B2 (en) | 2005-06-09 | 2012-04-17 | Li James J | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8541444B2 (en) | 2007-10-01 | 2013-09-24 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2009049492A1 (fr) * | 2007-10-12 | 2009-04-23 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Composés de diaryléthers multi-substitués et d'aniline d'hydrocarbures aromatiques n-substitués |
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9932311B2 (en) | 2013-10-08 | 2018-04-03 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015097713A1 (en) | 2013-11-14 | 2015-07-02 | Cadila Healthcare Limited | Novel heterocyclic compounds |
US10246470B2 (en) | 2013-11-14 | 2019-04-02 | Cadila Healthcare Limited | Heterocyclic compounds |
US10011609B2 (en) | 2013-11-14 | 2018-07-03 | Cadila Healthcare Limited | Heterocyclic compounds |
US10519115B2 (en) | 2013-11-15 | 2019-12-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015095256A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
EP3974413A1 (en) | 2013-12-19 | 2022-03-30 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
US9834563B2 (en) | 2013-12-19 | 2017-12-05 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
WO2015176640A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10000454B2 (en) | 2014-05-22 | 2018-06-19 | Merck Sharp & Dohme | Antidiabetic tricyclic compounds |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
US10131651B2 (en) | 2014-08-08 | 2018-11-20 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
WO2016019863A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11555029B2 (en) | 2018-02-13 | 2023-01-17 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP1810677A1 (en) | 2007-07-25 |
US20080021069A1 (en) | 2008-01-24 |
JPWO2006038738A1 (ja) | 2008-05-15 |
CA2583326A1 (en) | 2006-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006038738A1 (ja) | 受容体機能調節剤 | |
ES2353247T3 (es) | Derivados de (1h-indol-7-il)-pirimidin-2-il-amino)metadona y compuestos emparentados como inhibidores del igf-ri, para el tratamiento de cancer. | |
EP4097099B1 (en) | Heterocyclic glp-1 agonists | |
DE60112272T2 (de) | Imidazopyridin-derivate | |
US20090156582A1 (en) | Pyrazole Compound | |
CA2947002C (en) | Pyrazole compounds and their use as t-type calcium channel blockers | |
AU2016284942B2 (en) | NADPH oxidase 4 inhibitors | |
WO2006062224A1 (ja) | カルボキサミド誘導体 | |
WO2007055418A1 (ja) | アザ置換スピロ誘導体 | |
KR20060121818A (ko) | N-치환된 벤즈이미다졸릴 c-kit 억제제 | |
WO2007119833A1 (ja) | 含窒素複素環化合物 | |
EA016888B1 (ru) | Производные бензимидазола | |
DE102006016426A1 (de) | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren | |
WO2009022730A1 (ja) | P2x4受容体拮抗剤 | |
CA2993312A1 (en) | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists | |
WO2006108482A1 (de) | Purinderivate als inhibitoren von rezeptor-tyrosinkinase-aktivität | |
EP1473293B1 (de) | Chromenonderivate | |
EA037264B1 (ru) | Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство | |
WO2017060202A1 (en) | Triazole derivatives | |
CA3134952C (en) | Serotonin 5-ht2b inhibitory compounds | |
CA2868713A1 (en) | Aromatic ring compound | |
EP1957480A1 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
DE102006002649A1 (de) | Neuartige Aza-Heterozyklen als Kinase-Inhibitoren | |
DE102005019094A1 (de) | Neuartige Aza-Heterozyklen als Kinase-Inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006539360 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11664728 Country of ref document: US Ref document number: 2583326 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005793826 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005793826 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11664728 Country of ref document: US |